PT837052E - Derivados amino bicíclicos e antagonistas de pgd 2 contendo esses derivados - Google Patents

Derivados amino bicíclicos e antagonistas de pgd 2 contendo esses derivados Download PDF

Info

Publication number
PT837052E
PT837052E PT96918841T PT96918841T PT837052E PT 837052 E PT837052 E PT 837052E PT 96918841 T PT96918841 T PT 96918841T PT 96918841 T PT96918841 T PT 96918841T PT 837052 E PT837052 E PT 837052E
Authority
PT
Portugal
Prior art keywords
meoh
alkyl
chcl
compound
hydrogen
Prior art date
Application number
PT96918841T
Other languages
English (en)
Inventor
Tsunetoshi Honma
Akinori Arimura
Mitsuaki Ohtani
Tatsuo Tsuri
Junji Kishino
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of PT837052E publication Critical patent/PT837052E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/52—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/74—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/84—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/54—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C07C245/08—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C07C281/08—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones
    • C07C281/14—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones the carbon atom being further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/43—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C337/00—Derivatives of thiocarbonic acids containing functional groups covered by groups C07C333/00 or C07C335/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C337/06—Compounds containing any of the groups, e.g. thiosemicarbazides
    • C07C337/08—Compounds containing any of the groups, e.g. thiosemicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. thiosemicarbazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14—[b,f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/24—[b,e]-condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D337/14—[b,f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C07F9/5355—Phosphoranes containing the structure P=N-
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Description

DESCRIÇÃO "DERIVADOS AMINO BICÍCLICOS E ANTAGONISTAS DE PGD 2 CONTENDO ESSES DERIVADOS"
AREA DA INVENÇÃO A presente invenção refere-se a derivados amino biciclicos e a antagonistas da prostaglandina D2 (doravante, mencionada como PGD2) que contêm esses derivados.
ANTECEDENTES DA INVENÇÃO
Conhece-se alguns derivados amino biciclicos úteis como antagonistas de tromboxano A2 (TXA2) (Publicação de Patente Japonesa N° JP63-139161). No entanto, a Publicação de Patente Japonesa N° JP63-139161 descreve apenas os compostos como sendo úteis como antagonistas de TXA2 e não sugere a sua utilidade como antagonistas de PGD2.
Nomeadamente, sabe-se que o TXA2 possui actividades tais como acção contra a aglutinação de plaquetas, trombogénese, etc. Por conseguinte, os antagonistas de TXA2 têm sido considerados como sendo úteis como antitrombóticos e, também, no tratamento do enfarte do miocárdio ou asma através do antagonismo da TXA2. 0 documento EP-A-608847 descreve sulfonamidas carbo- ciclicas como agonistas ou antagonistas de PGEZ. 0 documento EP-A-312906 descreve derivados de sulfo- namida, os quais podem ser utilizados como antagonistas de txa2. O documento EP-A-0226346 descreve derivados de sulfo- namida biciclica, os quais podem ser utilizados como fármacos antitrombóticos, antivasoconstrictores e antibroncoconstricto-res. 0 documento EP-A-0150709 descreve análogos de pros-taglandinas de tipo 7-oxabiciclo-heptano como agentes cardiovasculares, os quais são úteis no tratamento de doença 1 trombolítica. 0 documento EP-A-0290285 descreve derivados de sulfo-namida bicíclica e a sua utilização no tratamento de doenças tais como angina do peito, enfarte do miocárdio e enfarte cerebral.
Um antagonista do receptor de TXA2, "S-1452", é descrito em Int. Arc. Allergy Immunol. (1992) 98, 239-246, Arimura et al., "Antiasthmatic Activity of a Novel Thromboxane A2 Antagonist, S-1452, in Guinea Pigs" (XP 00 291 6327).
Por outro lado, o antagonista de PGD2 da presente invenção é útil no melhoramento de estados provocados por uma produção excessiva de PGD2. Especificamente, ele é útil como um fármaco para tratar doenças nas guais está envolvida a disfunção de mastócitos, por exemplo, mastocitose sistémica e distúrbio da activação sistémica de mastócitos, e também a contracção da tragueia, asma, rinite alérgica, conjuntivite alérgica, urticária, lesão devido a reperfusão isguémica e inflamação.
Como é evidente do precedente, o antagonista de TXA2 e o antagonista de PGD2 são completamente diferentes um do outro em termos do sitio activo, mecanismo de acção e aplicação, e têm caracteristicas muito diferentes. Consequentemente, nunca se esperou que qualquer composto pudesse possuir estas actividades em simultâneo. A PGD2 é produzida pelas PGG e PGH2 a partir de ácido araquidónico através da acção de ciclooxigenase activada por estimulação imunológica e não imunológica e é o prostanoide principal que é produzido e libertado a partir de mastócitos. A PGD2 possui várias actividades fisiológicas e patológicas potentes. Por exemplo, a PGD2 pode produzir contracção forte da traqueia, a qual provoca a asma brônquica, e, num estado alérgico sistémico, ela pode dilatar os vasos periféricos, o que leva a um choque anafiláctico. Em especial, tem sido prestada muita atenção à ideia que a PGD2 é uma das substâncias responsáveis pelos primeiros sintomas de obstrução nasal na 2 rinite alérgica. Por conseguinte, propôs-se o desenvolvimento de um inibidor da biossintese de PGD2 ou um antagonista do receptor de PGD2 como um fármaco para redução da obstrução nasal. No entanto é provável que o inibidor da biossintese da PGD2 afecte muito a síntese de prostaglandinas noutros organismos sendo, por conseguinte, desejável o desenvolvimento de um antagonista (bloqueador) específico para o receptor de PGD2.
DESCRIÇÃO DA INVENÇÃO
Os actuais requerentes estudaram intensamente para desenvolver antagonistas (bloqueadores) do receptor de PGD2 específicos para o receptor de PGD2, e constataram que os compostos da fórmula (Ib) abaixo ou os seus sais possuem uma actividade potente como antagonistas do receptor de PGD2 e são química e bioquimicamente estáveis.
Em conformidade, a presente invenção proporciona um antagonista de PGD2 o qual compreende um composto da fórmula (Ib) :
m em que é
3
ou em que A é alquileno o qual está opcionalmente interrompido por um heteroátomo ou fenileno, contém um grupo oxo, e/ou tem uma ligação insaturada; B é hidrogénio, alquilo, aralquilo ou acilo; R é COORi, CH2OR2 ou CON(R3)R4;
Ri é hidrogénio ou alquilo; R2 é hidrogénio ou alquilo; R3 e R4 são, cada um, independentemente hidrogénio, alquilo, hidroxilo ou alquilsulfonilo;
Xi é uma ligação simples, fenileno, naftileno, tiofenodiilo, indolediilo ou oxazolediilo; X2 é uma ligação simples, -N=N-, -N=CH-, -CH=N-, -CH=N-N-, -CH=N-0-, -C=NNHCSNH-, -C=NNHCONH-, -CH=CH-, -CH(OH)-, -C (Cl) =C (Cl)-, - (CH2) n~ r etinileno, -N(R5)-, -N(R5i)CO-, -N(R52)S02-, -n (R53) CON (R54)-CON(R55)- -S02N(R56)-, -o-, -S-, -S0-, -S02-, -C0-, oxadiazolediilo, tiadiazolediilo ou tetrazolediilo; X3 é alquilo, alcenilo, alcinilo, arilo, aralquilo, grupo heterociclico, cicloalquilo, cicloalcenilo, tiazolinilide_ nometilo, tiazolidinilidenometilo, -CH=NR6 ou -N=C(R7)Rs; R5, R5i, R52, R53, R54, R55 e R56 são, cada um, hidrogénio ou alquilo; R6 é hidrogénio, alquilo, hidroxilo, alcoxilo, carbamoiloxilo, tiocarbamoiloxilo, ureido ou tioureido; R7 e R8 são, cada um, independentemente alquilo, alcoxilo ou arilo; e n é 1 ou 2; em que um substituinte cíclico pode ter um até três substituin 4 tes seleccionados do grupo constituído por nitro, alcoxilo, sulfamoilo, amino substituído ou não substituído, acilo, aciloxilo, hidroxilo, halogéneo, alquilo, alcinilo, carboxilo, alcoxicarbonilo, aralcoxi-carbonilo, ariloxicarbonilo, mesiloxilo, ciano, alceniloxilo, hidroxialquilo, trifluorometilo, alquiltio, -N=PPh3, oxo, tioxo, hidroxiimino, alcoxiimino, fenilo e alquilenodioxilo, ou o seu sal ou hidrato deste; com a condição de que estejam excluídos os compostos (a) em que Xi e X2 são uma ligação simples, e X3 é fenilo; (b) em que Xi é uma ligação simples, X2 é -0- e X3 é benzilo; (c) (d) :f)
*NHC0“0-C{CH3}3NHC0~0~CíCH3)3 (e)
Os compostos das fórmulas:
5 (d)
NHC0~0~C(CH3)3 estão excluídos do âmbito da reivindicação 1 deste pedido/patente a título de limitações, as quais foram introduzidas na especificação após apresentação do pedido. Um ou mais destes compostos surgem em cada um dos documentos EP-A-22 634 6, EP-A-290285 e Chem. Pharm. Buli. 37(6), 1524-1533, K. Seno, S. Hagishita, "Thromboxane A2 Receptor Antagonists III, Synthesis and Pharmacologycal Activity of 6,6-Dimethylbicyclo[3.1.1]heptane Derivatives with a Substituted Sulfonylamino Group C-2," XP2058537. Estes compostos foram renunciados como antecipações acidentais, de acordo com as Decisões Gl/03 e G2/03.
Exemplos de compostos mais preferidos incluem os da fórmula (Ib) em que R é COORi (Ri é como definido acima) ou um seu sal ou hidrato.
De modo semelhante, exemplos dos compostos da presente invenção incluem os da fórmula (Ib) em que Xi é um fenileno ou tiofenodiilo, X2 é uma ligação simples, -N-N-, -CH=CH-, etinileno, -0-, -S-, -C0-, -C0N(R55)- (R55 é como definido acima), -N(R5i)C0- (R5i é como definido acima) e X3 é fenilo, ou um seu sal ou hidrato.
Exemplos de formas de realização mais preferidas incluem aquelas em que B é hidrogénio, Xi e X2 são ambos uma ligação simples, X3 é tienilo, tiazolilo, tiadiazolilo, isotiazolilo, pirrolilo, piridilo, benzofurilo, benzimidazolilo, benzotieni- 6 lo, dibenzofurilo, dibenzotienilo, quinolilo ou um seu sal ou hidrato. De modo semelhante, os exemplos incluem aqueles em que Xi é fenileno, tiofenodiilo, indolediilo ou oxazolediilo, X2 é uma ligação simples, -N=N-, etinileno, -S- ou -0-, e X3 é arilo ou um grupo heterocíclico, ou um seu sal ou hidrato.
Os compostos da fórmula geral (Ib) são compostos novos sintetizados pelos actuais requerentes.
Os termos utilizados ao longo da presente especificação são como definidos abaixo. 0 termo "alquileno" significa uma cadeia alquileno C1-C9 linear ou ramificada, por exemplo, metileno, metilmetileno, dimetilmetileno, metiletilmetileno, etileno, trimetileno, tetrametileno, pentametileno, hexametileno, heptametileno, octametileno, nonametileno ou semelhantes. 0 alquileno acima pode estar interrompido por heteroátomo(s) (átomo de oxigénio, enxofre, azoto, ou semelhantes) ou fenileno (e. g., 1.4- fenileno, 1,3-fenileno, 1,2-fenileno ou semelhantes), contêm um grupo oxo, e/ou tem uma ou mais ligações duplas ou triplas em qualquer uma das posições da cadeia. Os exemplos incluem - (CH2) 2-0-CH2-, - (CH2) 2-0-(CH2) 2-, - (CH2) 2-0- (CH2) 3-, -(CH2)2-0-(CH2)4-, -(CH2)2-0-(CH2)5-, -(CH2)2-0-(CH2)6-, -(ch2)2-s-(CH2)2-, - (CH2)3-S- (CH2)2-, -ch2-s-ch2-, -ch2-s- (CH2) 4-, -ch2- N(CH3)-CH2-, -ch2-nh- (CH2)2-, -(CH2)2-N(CH2CH3)-(CH2)3-, - (CH2) 2— 1.4- fenileno-CH2-, - (CH2) 2-0-l, 3-fenileno-CH2-, - (CH2) 2-0-l, 2- fenileno-CH2-, - (CH2) 2-0-l,4-fenileno-CH2-, -CH=CH-S-CH2-1,4-fenileno-CH2-, -CH=CH-S-1,3-fenileno-(CH2) 2-, 2-oxopropileno, 3- oxopentileno, 5-oxo-hexileno, vinileno, 1-propenileno, 2-propenileno, 1-butenileno, 2-butenileno, 3-butenileno, 1.2- butadienileno, 1,3-butadienileno, 1-pentenileno, 2-pente-nileno, 3-pentenileno, 4-pentenileno, 1,2-pentadienileno, 1.3- pentadienileno, 1,4-pentadienileno, 2,3-pentadienileno, 2.4- pentadienileno, 1-hexenileno, 2-hexenileno, 3-hexenileno, 4- hexenileno, 5-hexenileno, 1,2-hexadienileno, 1,3-hexadie-nileno 1,4-hexadienileno, 1,5-hexadienileno, 2,3-hexadienileno 7 2.4- hexadienileno 2,5-hexadienileno, 3,4-hexadienileno, 3.5- hexadienileno, 4,5-hexadienileno, 1,l-dimetil-4-hexeni-leno, 1-heptenileno, 2-heptenileno, 3-heptenileno, 4-hepteni-leno, 5-heptenileno, 2,2-dimetil-5-heptenileno, 6-hepteni-leno, 1,2-heptadienileno, 1,3-heptadienileno, 1,4-heptadieni-leno, 1,5-heptadienileno, 1,6-heptadienileno, 2,3-heptadienileno, 2,4-heptadienileno, 2,5-heptadienileno, 2,6-heptadienileno, 3,4-heptadienileno, 3,5-heptadienileno, 3,6-heptadienileno, 4,5-heptadienileno, 4,6-heptadienileno ou 5,6-hepta-dienileno, 1-propinileno, 3-butinileno, 2-pentinileno, 5-he-xinileno, 6-heptinileno, - (CH2) -CH=CH-0- (CH2) 2-, -CH2-S-(CH2) 3-, —CH2—cis—CH=CH—1,2-fenileno-CH2-, -CH=CH-1,4-fenileno-(CH2) 2-, -4-OXO-4,5-hexenileno- e semelhantes. 0 termo "alquilo" significa cadeia alquilo C1-C20 linear ou ramificado, por exemplo, metilo, etilo, n-propilo, i-propilo, n-butilo, i-butilo, s-butilo, t-butilo, n-pentilo, 1- pentilo, neopentilo, t-pentilo, hexilo, heptilo, octilo, nonilo, decilo, undecilo, dodecilo, tridecilo, tetradecilo, pentadecilo, hexadecilo, heptadecilo, octadecilo, nonadecilo, icosilo e semelhantes. 0 termo "arilo" significa anel monocíclico ou condensado C6-Ci4, por exemplo, fenilo, naftilo (e. g., 1-naftilo, 2- naftilo), antrilo (e. g. , 1-antrilo, 2-antrilo, 9-antrilo), fenantrilo (e. g., 2-fenantrilo, 3-fenantrilo, 9-fenantrilo), fluorenilo (e. g., 2-fluorenilo) e semelhantes. É especialmente preferido o fenilo. 0 termo "aralquilo" significa um grupo obtido substituindo um alquilo como definido acima com um arilo acima em quaisquer posições substituíveis do alquilo. Os exemplos incluem benzilo, fenetilo, fenilpropilo (e. g. , 3-fenil-propilo), naftilmetilo (e. g., α-naftilmetilo), antrilmetilo (e. g., 9-antrilmetilo), fenantrilmetilo (e. g., 3-fenan-trilmetilo) e semelhantes. 0 termo "acilo" significa acilo Cq-Cg resultante de um ácido carboxilico alifático, por exemplo, formilo, acetilo, propionilo, butirilo, valerilo e semelhantes. 0 termo "alquilsulfonilo" significa um grupo obtido substituindo um sulfonilo com um alquilo acima, por exemplo, metilsulfonilo, etilsulfonilo, propilsulfonilo e semelhantes. 0 termo "alcenilo" é uma cadeia alcenilo C2-C2o linear ou ramificada, a qual corresponde a um alquilo acima contendo uma ou mais ligações duplas. Os exemplos incluem vinilo, 1-propenilo, 2-propenilo, 1-butenilo, 2-butenilo, 3-butenilo, 1.2- butadienilo, 1-pentenilo, 1,2-pentadienilo, 2-hexenilo, 1.2- hexadienilo, 3-heptenilo, 1,5-heptadienilo, e semelhantes. 0 termo "alcinilo" é um alcinilo C2-C2o de cadeia linear ou ramificada, o qual corresponde a um alquilo acima contendo uma ou mais ligações triplas. Os exemplos incluem etinilo, 1-propinilo, 2-propinilo, 1-butinilo, 2-butinilo, 3-butinilo e semelhantes. 0 termo "grupo heterocíclico" significa um grupo cíclico de 5-7 membros contendo um ou mais heteroátomos independentemente seleccionados do grupo constituído por um átomo de oxigénio, enxofre e/ou azoto no anel, que está opcionalmente condensado com um anel de carbono ou com outro grupo heterocíclico em quaisquer posições substituíveis. Os exemplos incluem pirrolilo (e. g., 1-pirrolilo, 3-pirrolilo indolilo (e. g. , 2-indolilo, 3-indolilo, 6-indolilo carbazolilo (e. g., 2-carbazolilo, 3-carbazolilo), imidazo-lilo (e. g., 1-imidazolilo, 4-imidazolilo) , pirazolilo (e. g., 1-pirazolilo, 3-pirazolilo), benzimidazolilo (e. g., 2-ben-zimidazolilo, 5-benzimidazolilo), indazolilo (e. g., 3-inda-zolilo) , indolizinilo (e. g., 6-indolizinilo), piridilo (e. g., 2-piridilo, 3-piridilo, 4-piridilo) , quinolilo (e. g., 8-quinolilo), isoquinolilo (e. g., 3-isoquinolilo), acridilo (e. g., 1-acridilo), fenantridinilo (e. g., 2-fenantridinilo, 3-fenantridinilo), piridazinilo (e. g., 3-piridazinilo), piri- 9 midinilo (e. g. , 4-pirimidinilo) , pirazinilo (e. g., 2-pira-zinilo), cinolinilo (e. g., 3-cinolinilo), ftaladinilo (e. g., 5-ftaladinilo), quinazolinilo (e. g., 2-quinazolinilo), isoxazolilo (e. g., 3-isoxazolilo, 4-isoxazolilo), benzisoxa-zolilo (e. g., 1,2-benzisoxazol-4-ilo, 2, l-benzisoxazol-3--ilo), oxazolilo (e. g., 2-oxazolilo, 4-oxazolilo, 5-oxazo-lilo), benzoxazolilo (e. g., 2-benzoxazolilo), benzoxadiazo-lilo (e. g., 4-benzoxadiazolilo), isotiazolilo (e. g. , 3-iso-tiazolilo, 4-isotiazolilo) benzisotiazolilo (e. g., 1,2--benzisotiazol-3-ilo, 2,l-benzisothizol-5-ilo), tiazolilo (e. g., 2-tiazolilo), benzotiazolilo (e. g., 2-benzotia-zolilo), tiadiazolilo (e. g., 1,2,3-tiadiazol-4-ilo), oxadiazolilo (e. g., 1,3,4-oxadiazol-2-ilo), di-hidroxa-diazolilo (e. g., 4,5-di-hidro-l,2,4-oxadiazol-3-ilo) , furilo (e. g., 2-furilo, 3-furilo), benzofurilo (e. g., 3-benzo-furilo), isobenzofurilo (e. g., 1-isobenzofurilo) , tienilo (e. g., 2-tienilo, 3-tienilo), benzotienilo (1-benzotienilo, 2-benzotienilo), tetrazolilo (e. g., 5-tetrazolilo), benzo-dioxolilo (e. g., 1,3-benzodioxol-5-ilo), dibenzofurilo (e. g., 2-dibenzofurilo, 3-dibenzofurilo), dibenzoxepinilo (e. g., dibenz[b,f]oxepin-2-ilo), di-hidrodibenzoxepinilo (e. g., di-hidrobenz[b,f]oxepin-2-ilo), cromenilo (e. g., 2H-cromen-3-ilo, 4H-cromen-2-ilo), dibenzotiepinilo (e. g., dibenzo[b,f]tiepin-3-ilo, di-hidrobenzo[b,f]tiepin-3-ilo), morfolinilo (e. g., 1,4-morfolin-4-ilo), fenotiadinilo (2-fenotiadinilo), ciclopentatienilo (e. g., ciclopenta-[b]tiofen-3-ilo), ciclo-hexatienilo (e. g., ciclo-hexa[b]tio-fen-3-ilo), ciclo-heptatienilo (e. g., ciclo-hepta[b]tiofen-3--ilo), dibenzotienilo (e. g., 2-dibentienilo) , dibenzopiranilo (e. g., 2-dibenzopiranilo), dibenzo-p-dioxilo (e. g., 2-di-benzo-p-dioxilo) e semelhantes. 0 termo "cicloalquilo" significa alquilo ciclico C3-C8, por exemplo, ciclopropilo, ciclobutilo, ciclopentilo, ciclo-hexilo e semelhantes. 10 0 termo "cicloalcenilo" significa alcenilo cíclico C3-C8, por exemplo, ciclopropenilo (e. g., 1-ciclopropenilo), ciclobutenilo (e. g., 2-ciclobuten-l-ilo), ciclopentenilo (1-ciclopenten-l-ilo), ciclo-hexenilo (1-ciclo-hexen-l-ilo) e semelhantes. 0 termo "alcoxilo" significa alcoxilo Ci-C6, por exemplo, metoxilo, etoxilo, n-propoxilo, i-propoxilo, n-butoxilo e semelhantes.
Exemplos de amino substituído na definição de "amino substituído ou não substituído" incluem aminos mono- ou dissubstituídos, tais como metilamino, etilamino, dimetilamino, ciclo-hexilamino, fenilamino, difenilamino ou amino cíclico tal como piperidino, piperadino ou morfolino. 0 termo "aciloxilo" significa um aciloxilo derivado do "acilo" acima, por exemplo, acetiloxilo, propioniloxilo, butiriloxilo, valeriloxilo e semelhantes. 0 termo "halogéneo" significa flúor, cloro, bromo e iodo. 0 termo "alcoxicarbonilo" significa um grupo alcoxi-carbonilo derivado do "alcoxilo" acima, por exemplo, metoxicarbonilo, etoxicarbonilo, feniloxicarbonilo e semelhantes . 0 termo "aralquiloxicarbonilo" significa um grupo aralquiloxicarbonilo derivado do "aralquilo" acima, por exemplo, benziloxicarbonilo, fenetiloxicarbonilo e semelhantes . 0 termo "ariloxicarbonilo" significa um grupo ariloxicarbonilo derivado do "arilo" acima, por exemplo, feniloxicarbonilo, naftiloxicarbonilo e semelhantes. 0 termo "alceniloxilo" significa um grupo alceniloxilo derivado do "alcenilo" acima, por exemplo, viniloxilo, 1-propeniloxilo, 2-buteniloxilo e semelhantes. 0 termo "hidroxialquilo" significa um grupo hidroxialquilo derivado do "alquilo" acima, por exemplo, hidroximetilo, hidroxietilo, hidroxipropilo e semelhantes. 11 0 termo "alquiltio" significa um grupo alquiltio derivado do "alquilo" acima, por exemplo, metiltio, etiltio, propiltio e semelhantes. 0 termo "alquilenodioxilo" significa alquilenodioxilo C1-C3, por exemplo, metilenodioxilo, etilenodioxilo, propile-nodioxilo e semelhantes.
No caso de "fenileno, "naftileno", "tiofenodiilo", "indolediilo", "oxazolediilo", "oxadiazolediilo" e tetra-zolediilo", o grupo referido pode ligar-se aos grupos vizinhos em quaisquer duas posições substituíveis.
Nas definições acima, quando um substituinte (s) é cíclico, ele pode estar substituído com um até três substituintes seleccionados de nitro, alcoxilo, sulfamoilo, amino substituído ou não substituído, acilo, aciloxilo, hidroxilo, halogéneo, alquilo, alcinilo, carboxilo, alcoxi-carbonilo, aralcoxicarbonilo, ariloxicarbonilo, mesiloxilo, ciano, alceniloxilo, hidroxialquilo, trifluorometilo, alquiltio, -N=PPh3, oxo, tioxo, hidroxiimino, alcoxiimino, fenilo e alquilenodioxilo. 0(s) substituinte(s) podem estar ligados em quaisquer posições substituíveis no anel.
Os exemplos de sais do composto (Ib) incluem os preparados com um metal alcalino (e. g., lítio, sódio ou potássio), um metal alcalino-terroso (e. g. , cálcio), uma base orgânica (e. g., trometamina, trimetilamina, trietilamina, 2-aminobutano, t-butilamina, diisopropiletilamina, n-butil-metilamina, ciclo-hexilamina, diciclo-hexilamina, N-isopro-pilciclo-hexilamina, furfurilamina, benzilamina, metil-benzilamina, dibenzilamina, N,N-dimetilbenzilamina, 2-cloro-benzilamina, 4-metoxibenzilamina, 1-naftilenometilamina, dife-nilbenzilamina, trifenilamina, 1-naftilamina, 1-aminoantrace-no, 2-aminoantraceno, desidroabietilamina, N-metilmorfolina ou piridina), um aminoácido (e. g., lisina ou arginina) e semelhantes. 12 0 termo "hidrato" significa um hidrato do composto da fórmula (Ib) ou um seu sal. Os exemplos incluem mono- e di-hidratos.
Os compostos da presente invenção são representados pela fórmula (Ib) e são inclusive da forma de quaisquer tipos de compostos estereoisoméricos (e. g., diastereómeros, epimeros, enantiómeros) e racémicos.
Os compostos da fórmula geral (Ib) podem ser preparados fazendo reagir um composto amino da fórmula geral (II) com um derivado reactivo de ácido sulfónico ou ácido carboxilico que corresponda à estrutura parcial: Z-X1-X2-X3 como se mostra a seguir.
em que A, B, R, Xi, X2, X3, Y são como definidos acima e Z é -C0-. Um ácido carboxilico que corresponde à referida estrutura parcial é um composto da fórmula geral X3-X2-Xi-COOH . Derivado reactivo destes ácidos carboxilicos significa um halogeneto correspondente (e. g., cloreto, brometo, iodeto), anidrido ácido (e. g., anidrido ácido misto com ácido fórmico ou ácido acético), éster activo (e. g., éster de succinimida), e os exemplos destes incluem geralmente agentes de acilação para a acilação do grupo amino. 0 ácido carboxilico X3-X2-Xi--COOH pode ser utilizado na reacção tal qual sem se converter num derivado reactivo, na presença de um agente de condensação (e. g., diciclo-hexilcarbodiimida (DCC), l-etil-3-(3-dimetila-minopropil)carbodiimida, N,Ν'-carbonildiimidazole) os quais 13 são utilizados na reacção de condensação entre aminas e ácidos carboxilicos. A reacção pode ser realizada nas condições geralmente utilizadas para a acilação do grupo amino. Por exemplo, no caso da condensação utilizando um halogeneto ácido, a reacção é realizada utilizando um solvente, tal como um solvente de tipo éter (e. g., éter dietílico, tetra-hidrofurano, dioxano) , solvente do tipo benzeno (e. g., benzeno, tolueno, xileno), solvente de tipo hidrocarboneto halogenado (e. g., diclorometano, dicloroetano, clorofórmio), acetato de etilo, dimetilformamida, sulfóxido de dimetilo, acetonitrilo ou semelhantes, se necessário, na presença de uma base (e. g., base orgânica, tal como trietilamina, piridina, N,N-dimetilaminopiridina, N-metilmorfolina; base inorgânica, tal como hidróxido de sódio, hidróxido de potássio, carbonato de potássio ou semelhantes) sob arrefecimento, à temperatura ambiente ou sob aquecimento, de um modo preferido a uma temperatura que varia desde -20 °C até uma temperatura sob arrefecimento, ou desde a temperatura ambiente até à temperatura de refluxo do sistema reaccional, durante vários minutos até várias h, de um modo preferido durante 0,5 h até 24 h, de um modo mais preferido, durante 1 h até 12 h.
As condições reaccionais para a reacção entre outro derivado reactivo ou um ácido livre e uma amina (II) podem ser determinadas de um modo convencional dependendo das caracteristicas do respectivo derivado reactivo ou ácido livre. O produto reaccional pode ser purificado por métodos de purificação convencionais, por exemplo, a extracção com um solvente, cromatografia, recristalização ou semelhantes.
Os exemplos específicos do composto (II) como um material de partida para o presente método são como se segue. Os exemplos do composto 3-amino[2.2.1]bicíclico incluem o ácido 7-(3-aminobiciclo[2.2.1]hept-2-il)-5-heptenóico, ácido 14 7-(3-aminobiciclo[2.2.1]hept-2-il)-2, 2-dimetil-5-heptenóico, ácido 7-(N-metil-3-aminobiciclo[2.2.1]hept-2-il)-5-heptenóico, ácido 6-(3-aminobiciclo[2.2.1]hept-2-il)-5-hexenóico. Os exemplos específicos do composto 2-amino-6, 6-dimetil [3.1.1] bicícli_ co incluem o ácido 7-(2-amino-6,6-dimetilbiciclo[3.1.1]hept-3--il)-5-heptenóico. Nestes compostos de partida, a cadeia de ácido heptenóico pode estar saturada para formar uma cadeia de ácido heptanóico interrompida por um heteroátomo (s) ou um heterogrupo (s) tal como -0-, -S-, -NH-, ou um fenileno(s), ou substituída com um grupo oxo. Os exemplos de tais compostos incluem o ácido 7-(3-aminobiciclo[2.2.1]hept-2-il)heptanóico, ácido 4 —[2 —(2-aminobiciclo[3.1.1]hept-3-il)etoxifenilacético, ácido 7-(3-aminobiciclo[2.2.1]hept-2-il)-6-oxo-heptanóico.
Estes compostos de partida são descritos na Publicação de Patente Japonesa N° JP 63-139161 ou JP 01-52751, ou podem ser preparados segundo o método ali descrito. 0 ácido carboxílico X3-X2-X1-COOH que corresponde à estrutura parcial Z-X1-X2-X3 significa um ácido carboxílico com substituintes que correspondem aos X acima. Isto é, os exemplos incluem o ácido alcano-carboxílico, ácido alceno-carboxílico, ácido alcino-carboxílico, ácido cicloalcano- carboxílico, ácido cicloalceno-carboxílico, ácido aril-carboxílico, ácido aralquiloxi-carboxílico, ácido carboxílico substituído com heterociclo, ácido heteroarilalquil-carboxílico e ácido amino-carboxílico substituído. Cada um dos ácidos carboxílicos pode ter um substituinte(s) anterior. Estes ácidos carboxílicos estão comercialmente disponíveis ou podem ser facilmente sintetizados a partir de composto(s) conhecido(s) segundo um método conhecido. Na reacção, o ácido carboxílico pode ser convertido no derivado reactivo correspondente acima, se necessário. Por exemplo, quando é necessário um halogeneto ácido, o composto é feito reagir com halogeneto de tionilo (e. g., cloreto de tionilo), halogeneto de fósforo (e. g., tricloreto de fósforo, pentacloreto de 15 fósforo) ou halogeneto de oxalilo (e. g., cloreto de oxalilo) segundo um método conhecido como os descritos na literatura (e. g.r Shin-Jikken-Kagaku-Koza, vol. 14, pág. 1787 (1978);
Synthesis, 852-854 (1986); Shin-Jikken-Kagaku-Koza, vol. 22, pág. 115 (1992)). Os outros derivados reactivos também podem ser preparados segundo métodos conhecidos.
Entre os compostos (Ib) alvo, agueles em gue a cadeia lateral A contém uma ligação insaturada, em especial uma ligação dupla, também podem ser preparados fazendo reagir um derivado aldeído da fórmula geral (III) abaixo com um composto ileto que corresponde ao remanescente da cadeia lateral A-R nas condições da reacção de Wittig:
em que A, B, R, Xi, X2, X3, Y são como definido acima e Z é -C0-. 0 composto de partida (III) pode ser preparado segundo um método descrito, por exemplo, na Publicação de Patente Japonesa N° JP 02-256650. Além disso, um composto ileto que corresponde ao remanescente da cadeia A-R pode ser sintetizado fazendo reagir trifenilfosfina com um ácido alcanóico halogenado correspondente, ou um derivado éster, derivado éter ou derivado amida na presença de uma base segundo um método conhecido.
Entre os compostos (Ib) alvo, aqueles em que R é COOH podem ser convertidos num derivado éster, derivado álcool, derivado éter, derivado amida correspondente, se desejado. Por 16 exemplo, os derivados éster podem ser preparados esterifiçando um ácido carboxílico de um modo convencional. Um derivado éster, quando reduzido, dá um derivado álcool e um amidado dá um derivado de amida. Um derivado éter pode ser obtido por O-alquilação de um derivado álcool. 0 composto (Ib) da presente invenção exibe um efeito antaqonista contra a PGD2 in vitro através da ligação ao receptor PGD2, e é útil como um fármaco para tratar doenças nas quais está envolvida a disfunção de mastócitos devido à produção excessiva de PGD2. Por exemplo, o composto (Ib) é útil como um fármaco para tratar doenças, tais como a mastocitose sistémica e um distúrbio da activação sistémica de mastócitos, e também a contracção da traqueia, asma, rinite alérgica, conjuntivite alérgica, urticária, lesão devido a reperfusão isquémica e inflamação. 0 composto (Ib) apresenta um efeito preventivo na obstrução nasal in vivo e, por conseguinte, é especialmente útil como um fármaco para a tratar.
Quando se utiliza um composto (Ib) da presente invenção em tratamento, ele pode ser formulado em formulações correntes para administração oral e parentérica. Uma composição farmacêutica contendo um composto (Ib) da presente invenção pode estar numa forma para administração oral e parentérica. Especificamente, ele pode ser formulado em formulações para administração oral tais como comprimidos, cápsulas, granulados, pós, xarope e semelhantes; nas para administração parentérica, tal como solução ou suspensão injectável para injecção intravenosa, intramuscular ou subcutânea, inalador, gotas oftálmicas, gotas nasais, supositórios ou formulações percutâneas, tal como pomadas.
Ao preparar as formulações pode utilizar-se veículos, excipientes, solventes e bases conhecidas do técnico médio na matéria. No caso de comprimidos, eles são preparados prensando ou formulando um ingrediente activo em conjunto com 17 componentes auxiliares. Exemplos de componentes auxiliares utilizáveis incluem excipientes farmaceuticamente aceitáveis, tais como aglutinantes (e. g., amido de milho), enchimentos (e. g., lactose, celulose microcristalina) , desintegrantes (e. g., amido glicolato de sódio) ou lubrificantes (e. g., estearato de magnésio). Os comprimidos podem ser apropriadamente revestidos. No caso de formulações liquidas, tais como xaropes, soluções ou suspensões, elas podem conter agentes de suspensão (e. g., metilcelulose), emulsionantes (e. g., lecitina), conservantes e semelhantes. No caso de formulações injectáveis, elas podem estar na forma de soluções ou suspensões, ou emulsões oleosas ou aquosas, as quais podem conter agentes de estabilização de suspensão ou dispersantes, e semelhantes. No caso de um inalador, ele é formulado numa formulação liquida aplicável num inalador. No caso de gotas oftálmicas, ela é formulada numa solução ou numa suspensão. Especialmente, no caso de um fármaco nasal para tratar a obstrução nasal, ele pode ser utilizado como uma solução ou suspensão preparada por um método de formulação convencional, ou formulado como um pó utilizando um agente em pó (e. g., hidroxipropilcelulose, carbopole) , os quais são administrados na cavidade. Alternativamente, ele pode ser utilizado como um aerossol depois de embalar num recipiente especial com um solvente de baixo ponto de ebulição.
Embora a dosagem apropriada do composto (Ib) varie em função da via de administração, idade, peso corporal, género ou estado do doente, e do tipo de fármaco (s) utilizados em conjunto, se algum, e deva ser determinada, em última análise, pelo médico, no caso da administração oral, a dosagem diária pode estar geralmente entre cerca de 0,01-100 mg, de um modo preferido cerca de 0,01-10 mg, de um modo mais preferido cerca de 0,1-10 mg, por kg de peso corporal. No caso de administração parentérica, a dosagem diária pode estar geralmente entre cerca de 0,001-100 mg, de um modo preferido cerca de 0,001-1 mg, de um modo mais preferido cerca de 0,01-1 18 mg, por kg de peso corporal. A dosagem diária pode ser administrada em 1-4 divisões.
Os Exemplos seguintes são proporcionados para ilustrar adicionalmente a presente invenção e não são para ser interpretados como limitando o âmbito desta.
Exemplo 1
(Π-2)
(lk-11) (lk-12)
Dissolveu-se trifluoroacetato de (Z)-7-[(IS,2R,3R,4R)-3-aminobiciclo[2.2.1]hept-2-il]-5-heptenoato de metilo (II-2) (232 mg, 0,636 mmol), o qual foi preparado pelo método descrito no Exemplo de Referência 4 da Publicação de Patente Japonesa N° JP 63-139161, em cloreto de metileno (5 ml). À solução adicionou-se trietilamina (0,279 mL, 2,00 mmol) e cloreto de 4-bifenilcarbonilo sob arrefecimento em gelo e agitou-se durante 7 h à mesma temperatura. Purificou-se a mistura reaccional por cromatografia em coluna sobre sílica gel (acetato de etilo/n-hexano (1:4)) para produzir (Z)-7--[(IS,2R,3R,4R)-3-(4-bifenil)carbonilaminobiciclo[2.2.1]hept--2-il]-5-heptenoato de metilo (lk-11) (221 mg, 0,512 mmol).
Dissolveu-se o composto (lk-11) (190 mg, 0,440 mmol) em metanol (6 mL). À solução adicionou-se KOH 1 N (1,10 mL, 1,10 mmol) sob arrefecimento em gelo e agitou-se durante 15 h à temperatura ambiente. Concentrou-se a mistura reaccional in vacuo. Extraiu-se o resíduo, após a adição de água (20 mL) e HC1 1 N (2 mL) , com acetato de etilo. Lavou-se a camada orgânjL 19 ca com solução aquosa saturada de cloreto de sódio, secou-se sobre sulfato de sódio anidro e concentrou-se. Purificou-se o resíduo por cromatografia em coluna sobre sílica gel (acetato de etilo/hexano (1:1) contendo 0,3% de ácido acético) para produzir ácido (Z)-7-[(IS,2R,3R,4R)-3-(4-bifenil)carbonilami-nobiciclo[2.2.1]hept-2-il]-5-heptenóico (lk-12) (172 mg, 0,412 mmol). Rendimento 94%.
Os compostos seguintes também podem ser preparados do mesmo modo.
Os compostos preparados de acordo com o método descrito no Exemplo anterior são mostrados nos Quadros abaixo.
Quadro lk
N° Ri X!-X2-X3 lk-1 H lk-2 ch3 lk-3 H lk-4 H -*=—o~o lk-5 H —O 20 (continuação)
N° Ri X1-X2-X3 lk-6 H -O lk-7 H '™0“ohQ lk-8 H —Oo-O-OH lk-9 H lk-10 H -hQ-ohQ^och, lk-11 ch3 lk-12 H ^0“0 lk-13 H —Ok"^n”jO~oc^ lk-14 H 0 li lk-15 H lk-16 H lk-17 H “^Ol lk-18 H -OnrO lk-19 H OCHj lk-20 H -Q-s-Q 21
Quadro lm H N° Ri X1-X2-X3 lm-1 C"3 lm-2 \..t / w/ lm-3 CH3 /2=\ /^\ — lm-4 Vww/ VvrtV' lm-5 0 H 3 /yt y222\ *“\ )~*&**~ί } lm-6 ^ W \.....J lm-7 CH3 -O-.-O lm-8 lm-9 CH3 -0-0-0«. lm-10 lm-11 CH3 rzz\ /=\ lm-12 H w w lm-13 -O"°“0"oc^ lm-14 Vl.l. ..«»* \p..rf lm-15 ch3 /^K /^x --4. rt~QAc lm-16 T_T * - - t** ri lm-17 CH3 /i=\ —Λ—OH lm-18 \...>y v..,y lm-19 lm-2 0 ^ vv v-^y lm-21 H - 22 (continuação) N° Ri X1-X2-X3 lm-22 H —-OO lm-23 Bí ”7 *...... -Ο lm-24 H v~y lm-25 CH3 —V —O Ac lm-2 6 j~ j lm-27 ch3 ““W Λ~οη lm-2 8 H ^ lm-2 9 ch3 —d /V-OCHa lm-30 V..»/ lm-31 -0“='η"0 lm-32 H /=\ ?t ΓΛ “^JKC-N_O lm-33 H -Q£> lm-34 H CH3O. - /“Λ lm-35 H ÇHaOv — lm-3 6 H /=\ /=®\ —^ /)—N~N—4 /r-OCHj lm-37 H CHjO lm-38 H 0 ,OCHa /“=\ li /=< ~Λ_^°1Γ\_^ΟΟΗϊ OCHj 23 (continuação) N° Ri Xi-X2-X3 lm-3 9 H o -14 X» }~°CH3 OCHg lm-40 H O OCHa V-OCHa \wkhW ^ OCHa Quadro 2a 's*^vNHCOX1-Xj-X3 N° Ri X1-X2-X3 2a-l 2a-2 ch3 H -0-0 2a-3 ch3 2a-4 H -hQ^n^Q 2a-5 Na 2a-6 ch3 Γ\ 2a-7 H 2a-8 2a-9 ch3 H /»*% —V Λ'-'ΟΗΟ 2a-l 0 2a-l 1 ch3 H "0~V*nh w 24 (continuação) N° Ri X1-X2-X3 2a-12 2a-13 ch3 H -Ογ. s*~£ $ 2a-14 ch3 2a-15 H 2a-l 6 ch3 ~\J~\ 2a-17 H 0 2a-l 8 ch3 0 2a-l 9 H XrhO 2a-2 0 ch3 2a-21 H "Ό 2a-22 Na 2a-23 ch3 0 2a-24 H rsssv j| jrassv 2a-25 2a-2 6 ch3 H -«*-0-0 2a-27 2a-2 8 ch3 H -0°-£> 2a-2 9 ch3 2a-30 H 2a-31 ch3 ”0-Vn-^Q> 2a-32 2a-33 ch3 H ~~Ç)~^-uOí 2a-34 2a-35 ch3 H -Q.....^.....0 25 N° Ri 2a-36 ch3 2a-37 H 2a-38 ch3 NO 1 00 H 2a-4 0 ch3 2a-41 H 2a-42 ch3 2a-43 H 2a-44 ch3 2a-45 H 2a-4 6 ch3 2a-47 H 2a-4 8 ch3 2a-49 H 2a-50 ch3 2a-51 H 2a-52 ch3 2a-53 H 2a-54 ch3 2a-55 H 2a-56 ch3 2a-57 H 2a-58 ch3 2a-59 H 2a-60 ch3 (continuação) X1-X2-X3
(continuação)
N° Ri X1-X2-X3 2a-64 2a-65 ch3 H /-V O O-' 2a-66 2a-67 ch3 H 2a-68 ch3 «sv 2a-69 H O 2a-7 0 2a-71 ch3 H —C ^—OAc 2a-72 2a-73 ch3 H -OO-on 2a-74 2a-7 5 ch3 H -O-ohQ-cch, 2a-7 6 2a-77 ch3 H -^ --OAC 2a-7 8 2a-7 9 ch3 H -00» 2a-80 ch3 2a-81 H 2a-82 2a-83 ch3 H ~0“oac 2a-84 2a-85 ch3 H 2a-86 2a-87 ch3 H ~^O~0CH5 2a-88 2a-89 ch3 H "ÇO 0 2a-90 ch3 -Q 2a-91 H 27 (continuação) N° Ri X1-X2-X3 2a-92 ch3 -O 2a-93 H s 2a-94 ch3 1 cn H ~ir\ 2a-96 Na 2a-97 Ca1/2 2a-98 2a-99 ch3 H -0-0 2a-l0 0 ch3 2a-l01 H 2a-l02 ch3 Q-ch, 2a-103 H 0 J 2a-104 ch3 ~~^Ç^~-och3 2a-105 H 0CH3 2a-l0 6 ch3 H .p 2a-107 H r=\ N _/ \_) T 2a-l0 8 ch3 2a-l0 9 H -0-0 2a-l10 Na 2a-l11 2a-l12 ch3 H 2a-113 2a-114 ch3 H -0-3 2a-115 2a-l16 ch3 H —Och> 2a-117 2a-l18 ch3 H 2a-l19 H -Ç> OAc 28 (continuação) N° Ri X1-X2-X3 2a-12 0 H OH 2a-121 H -p 2a-122 H O 2a-123 H 1 0 Ò 2a-124 H -ch=-Ç) OH 2a-125 H 2a-126 H —^ ^—8# 2a-127 H — W Η r 2a-12 8 H irO 2a-12 9 H ΌΟ 2a-130 H ~J~\ O 2a-131 H ~Ç} b 2a-132 H 2a-133 H HÕ 29 (continuação)
N° Ri X1-X2-X3 2a-134 H "chjohQ 2a-135 H xo 2a-136 H 2a-137 H ^*—OCgHg : 2a-138 H —°CH(CHj)2 2a-139 H H 2a-140 H XO H 2a-141 H 2a-142 H O HjCO 2a-143 H HO^O 2a-144 H hyo 2a-145 H o-to 2a-14 6 H /=\ 9 /=\ 2a-147 H 30 (continuação)
N° Ri X1-X2-X3 2a-148 H 2a-14 9 H -=-0 2a-150 H 2a-151 H v 2a-152 H 2a-153 H 2a-154 H -Q-e* ............s.................. 2a-155 H -ço 2a-156 H ~0$ H 2a-157 H Τ'- «Λ" 2a-158 H V· 2a-159 H o-< 2a-l60 H -9 HOOC 2a-l61 H *V>-<n s 2a-l62 H /«SN ΛΓ— NOj 2a-l63 H “O 31 (continuação)
N° Ri X1-X2-X3 2a-l64 H 2a-l65 H 2a-l6 6 H Ό·°Όλ 2a-l67 H 2a-l68 H 2a-l6 9 H ^Q-s-Q-ocn, 2a-170 H -Γ0 S 2a-171 H H Rs^CHi 2a-172 H 2a-173 H V~* 2a-174 H V/8r Q 2a-175 H 2a-17 6 H w* 2a-177 H Q \,OCH, Q 32 (continuação) N° Ri
2a-178 H
2a-17 9 H
2a-l8 0 H
2a-l81 H
2 a—18 2 H
2a-183 H
2a-184 H
2a-185 H
2a-186 H
2a-187 H
2 a—18 8 H
2a-189 H
2a-l90 H X1-X2-X3
33 (continuação) N° Ri
2a-l91 H
2a-l92 H
2a-l93 H
2a-l94 H
2a-195 H
2a-196 H
2a-l97 H
2a-l98 H
2a-l99 H
2a-2 0 0 H
2 a-201 H
2a-2 02 H X1-X2-X3
34 (continuação) N° Ri X1-X2- 2a-203 H V 2a-204 2a-205 2a-2 0 6 Ya 2a-207 2a-2 0 8 2a-2 0 9 2a-210 2a-211 Vkx”1· S CHs 2a-212 S^VcHj 2a-213 W 2a-214 Vv 2a-215 2a-216 ^0 35 (continuação) N° Ri 2a-217 2a-218 2a-219 2a-22 0 2a-221 2a-222 2a-223 2a-224 2a-225 2a-22 6 2a-227 2a-22 8 X1-X2-X3
36 N°
Ri 2a-22 9 2a-230 2a-231 2a-232 2a-233 2a-234 2a-235 2a-236 2a-237 2a-238 2a-239 (continuação) X1-X2-X3 PHs
ξ CHa CHo
H,Cq
. //
HgCO
% /“S“^ // H$c
H3CO
OCHj
37 (continuação) N° Ri X1-X2-X3 2a-240 h3c ~-0"s"0 HjCO 2a-241 CH, ~~ÇjhOCHi 2a-242 .CH3 OCWj 2a-243 CHj HjCO 2a-244 OCR, h^c 2a-245 ochj ~C^sHQ 0½ 2a-24 6 OCHj ”C^s™0~cH5 2a-247 OCHj HjCO 2a-248 PCHs 0CH3 2a-24 9 OCHj —çy*o** 2a-250
HOHjC 38 N°
Ri (continuação) X1-X2-X3 2a-251 2a-252 2a-253 2a-254 2a-255 2a-256 2a-257 2a-258 2a-259 2a-2 60
39 (continuação) N°
Ri X1-X2-X3 2a-2 61 2a-2 62 2a-2 63 2a-2 64 2a-2 65 2a-2 6 6 2a-2 67 2a-2 68 2a-2 6 9 2a-270 2a-271 2a-272 2a-273
40 (continuação) N° Ri X1-X2-X3 2a-274 2a-275 2a-27 6 2a-277 Χ<£β 2a-278 xço CM» 2a-27 9 XXJO CjHs 2a-2 8 0 Ό0ΟΙ coch, j 2a-2 81 XOO H 2a-2 82 £CQ CH» 2a-283 XCO CaM5 2a-284 £¢0 COCH3 (continuação) N° Ri X1-X2-X3 2a-2 8 6 ttp M 2a-287 tro N CH3 2a-2 8 8 Xjcfl 2a-2 8 9 XjcD COCHj 2a-2 90 Xkf) H 2a-2 91 -CçP CHj 2a-2 92 -Qp 2a-2 93 XjcQ N COCH^ 2a-2 94 2a-2 95 i-m\ Ο λ»ϊ\ CHj 2a-2 96 .OCH3 OCHj 2a-2 97 -0^0-* 2a-2 98 —O~£'h"O"0chí 42 (continuação)
N° Ri X1-X2-X3 2a-2 99 HaCO OCHj CJCB, 2a-300 /=\ 9 /=\ PH» 2a-301 -OVp HjC 2a-302 2a-303 -0^0 X^wnl Vm*/ 2a-304 0 —ΐ—OCHj OCHj 2a-305 Ο 2a-306 *^C^H ^”~C^”0CH3 2a-307 H5CO OCHj h=\ 9 /=^ —\> >T~ocH3 OCHj 2a-308 /=\ 9 /=\ .CR, 2a-309 /=\ 9 /==\ -Oii·0·)./ HgC 2a-310 O ~^O^h"0 w“0“OC^ OCHj 2a-311 ~0~:fê'!r£D h3c 43 (continuação) N° Ri X1-X2-X3 2a-312 -Q-Jj-C-JHQ-OH 2a-313 -O-r-tQ-»1* 2a-314 /=\ 9 /=\ PH. 2a-315 HgCO OCHj ™V^h"^"h \_^~0CM3 0CN9 Quadro 2b ts^A*N-COXl-Xz-X3 CHj N° Ri X1-X2-X3 2b-l H 0 2b-2 H ~ΤΛ $ 44
Quadro 2c
N° Ri X1-X2-X3 2c-l H -O 2c-2 H -O 2c-3 H
Quadro 2d N° 2d-l 2d-2
Ri X1-X2-X3
H
H
Quadro 2e
N° Ri X1-X2-X3 2e-l H -o°-o 2e-2 H “O 2e-3 H T) s Quadro 2f 0^°'O-/COOR' ^Α'ΝΗΟΟ·Χ,·Χ3.Χ3 N° Ri X1-X2-X3 2f-l H -o-^-o 2 f-2 H r\ "\J 2f-3 H ~Q 46
Quadro 2g N° 2g-l
R3 X1-X2-X3
H SO2CH3
Quadro 2h
N° X!-X2-X3
2h-l 'O 2h-2 2h-3 2h-4 -OsO 2h-5 2h-6 “O3 O 47
Quadro 2i
N° X1-X2-X3 2i-l 2 i-2 S V=H, 2i-3 s 2i-4 2i-5 /==\ /=\ 2i-6 “O^ 48
Quadro 2j
N° X1-X2-X3 2 j-1 'h 2 j-2 S 2 j — 3 2 j -4 -0-0 2 j — 5 -OoO 2 j-6 0 49 N° 2k-l 2k-2 2k-3
Quadro 2k
X1-X2-X3
50 (continuação) N° X1-X2-X3 2k-4 ~0"s_0 2k-5 2k-6
As propriedades físico-químicas dos compostos anteriores são indicados abaixo. 0 número do composto abaixo corresponde ao descrito no Quadros acima. N° lk-1 [a] D= -25,4° (CHC13, c=l, 0 8, 23 °C) . N° lk-2 CDCI3 200 MHz 1,07-2,28 (14H, m) , 2,32(2H, t, J=7,4 Hz), 2,63(1H, m) , 3,63(3H, s), 3, 93(1H, m) , 5, 30-5, 52 (2H, m) , 6,35(1H, d, J=7,0
Hz), 7,48-7, 60 (3H, m) , 7, 88-8,02 (6H, m) . IV (CHCI3) : 3438, 3002, 2946, 2868, 1727, 1652, 1514, 1485, 1363, 1310, 1245, 1154/cm.
[a] D= -80,4° (CHCI3, c=l, 01, 24,0 °C) . N° lk-3 CDCI3 200 MHz 1, 10-2,26 (14H, m) , 2,37(2H, t, J=7,2 Hz), 2,60(1H, m) , 3, 93(1H, m) , 5, 30-5,50(2H, m) , 6,33(1H, d, J=7,5 Hz), 7,48- 7,58(3H, m), 7,88-7,99(6H, m). 51 IV (CHCla) : 3446, 3004, 2952, 2874, 1709, 1652, 1515, 1485, 1305, 1153/cm.
[α] D= -96,4° (CHC13, c=l, 05, 23, 0 °C) . N° lk-4 CDCI3 300 MHz; 1,05-2, 17 (14H, m) , 2,38(2H, t, J=7,2 Hz), 2,52 (1H, m) , 3,81(1H, m) , 5,33-5,50 (2H, m) , 6,08(1H, d, J=7, 6
Hz), 7,39-7,53 (3H, m), 7,57-7, 62 ( 6H, m) . IV (CHCI3) : 3420, 3250, 3008, 2948, 2870, 2660, 2208, 1735(sh), 1705, 1640, 1500/cm.
[a] D= -21,9±0,6° (CHCI3, c=l, 02, 22 °C) . N° lk-5 CDCI3 300 MHz; 1,05-2,14(14H, m), 2,38(2H, t, J=7,2 Hz), 2,51(1H, m) , 3, 81(1H, m) , 5, 34-5, 46 (2H, m) , 6,07(1H, d, J=7,6
Hz), 7,33-7,56(5H, m) . IV (CHCI3) : 3422, 3250, 3010, 2950, 2876, 2664, 2558, 2210, 1735 (sh), 1705, 1645, 1502, 1441, 1410, 1307, 1276/cm.
[a] D= -63,6+1,9° (CHC13, c=0,56, 22 °C) . N° lk-6 CDCI3 300 MHz 1, 04-2,24 (14H, m), 2,36(2H, t, J=7,5 Hz) , 2,58 (1H, m) 3,8 8(1H, m) , 5,30-5,43 (2H, m) , 6,21 (1H, d, J=7,2 Hz) 7,41-7,49 (3H, m) , 7,73-7,77 (2H, m) . IV (CHCI3): 3447, 3011, 2955, 1708, 1653, 1603, 1578 1515, 1486, 1457, 1312, 1211, 1164/cm.
[a] D= -60,3° (CHCI3, c=l, 0 0, 23 °C) . 52 N° lk-7 CDCI3 300 ΜΗζ 1, 04-2,22(14Η, m) , 2,36(2Η, t, J=7,2 Hz), 2,57(1H, m) , 3,87(1H, m) , 5,30-5,44(2H, m) , 6,17(1H, d, J=8,7 Hz), 6,99-7,40(7H, m), 7,73(2H, d, J=7,5 Hz). IV (CHCI3): 3449, 3013, 2955, 1739, 1708, 1651, 1609, 1588, 1522, 1487, 1243, 1227, 1169/cm.
[a] D= -60,2° (CHCI3, c=0, 92, 23 °C) . N° lk-8 CDCI3 300 MHz 1, 04-2,25(14H, m) , 2,34(2H, t, J=7,5 Hz), 2,56(1H, m) , 3,87(1H, m) , 5, 30-5,44(2H, m) , 6,19 (1H, d, J=7,5 Hz), 6, 83-6, 94 ( 6H, m) , 7,69 (2H, d, 11 00 > Hz) . IV (CHCI3) : 3599, 3455, 3012 , 2955, 1711, 1644, 1604, 1577, 1524, 1507, 1492, 1290, 1236, 1197, 1170/cm. [a] D= -47,7° (CHCI3, c=l, 01, 22 °C) . N° lk-9 CDCI3 300 MHz 1, 04-2,20(14H, m) , 2,31(3H, s) , 2,36(2H, t, J=7,2 Hz), 2,56 (1H, m) , 3,86(1H, m) , 5, 30-5, 43 (2H, m) , 6,16(1H, d, J=7,2
Hz), 7,00-7,11(6H, m), 7,74(2H, d, J=8,7 Hz). IV (CHCI3) : 3450, 3010, 2955, 1750, 1709, 1651, 1609, 1596, 1523, 1489, 1370, 1247, 1227, 1183/cm.
[a] D= -54,7° (CHCI3, C=1, 01, 22 °C) . N° lk-10 CDCI3 300 MHz 53 1,04-2,22 (14Η, m) , 2,35(2H, t, J=7,2 Hz), 2,56(1H, m) , 3,82(3H, s), 3,8 6(1H, m) , 5,30-5,43(2H, m) , 6,17(1H, d, J=6, 9
Hz), 6,89-7,01(6H, m), 7,70(2H, d, J=8,7 Hz). IV (CHC13): 3023, 2955, 1742, 1708, 1649, 1613, 1602, 1577, 1522, 1507, 1490, 1227, 1210, 1170/cm.
[a] D= -58,1° (CHCI3, c=l, 01, 22 °C) . N° lm-1 CDCI3 300 MHz 1, 06-2,25(14H, m) , 2,32(2H, t, J=7,4 Hz), 2,61(1H, m) , 3, 63(3H, s), 3, 91(1H, m) , 5, 33-5, 47 (2H, m) , 6,24(1H, d, J=6,9
Hz), 7,35-7,38 (3H, m) , 7,53-7, 60(4H, m) , 7,78(2H, m) . IV (CHCI3): 3438, 3008, 2946, 2875, 2212, 1732, 1650, 1605, 1519, 1496/cm.
[a] D= +76° (CHCI3, c=l, 39, 24 °C) . N° lm-2 CDCI3 300 MHz 1, 05-2,20(14H, m) , 2,36(2H, t, J=6,2 Hz), 2,59(1H, m) , 3,8 9(1H, m) , 5,29-5,48 (2H, m), 6,26(lH, d, J=7,0 Hz), 7,26-7,38 (3H, m) , 7,52-7, 60 (4H, m) , 7,73-7,77 (2H, m) . IV (CHCI3) : 3444, 3012, 2952, 2874, 2664, 2214, 1718(sh), 1708, 1649, 1605, 1520, 1498/cm.
[a]D= +81,4° (CHCI3, c=l,01, 23 °C) . N° lm-3 CDCI3 300 MHz 1, 06-2,23 (14H, m) , 2,32(2H, t, J=7,0 Hz), 2,62(1H, m) , 3,63(3H, s), 3, 93(1H, m) , 5, 30-5, 50 (2H, m) , 6,28(1H, d, J=7,0
Hz), 7,38-7,51(3H, m) , 7,58-7, 67(4H, m) , 7, 83-7, 88(2H, m) . 54 IV (CHC13) : 3438, 3008, 2948, 2875, 1783(w), 1727, 1650, 1608, 1580(w), 1523, 1501, 1482/cm.
[a] D= +59° (CHC13, C=1,4 9, 25 °C) . N° lm-4 CDCI3 300 MHz 1, 08-2,25(14H, m) , 2,36(2H, t, J=7,4 Hz), 2,59(1H, m) , 3,91(1H, m) , 5,28-5, 48(3H, m) , 6,29(1H, d, J=7,4 Hz), 7,38-7,50(3H, m), 7,61-7,67(4H, m), 7,81-7,86(2H, m). IV (CHCI3) : 3436, 3010, 2948, 2868, 1727, 1715(sh), 1649, 1615(w), 1524, 1502, 1482, 1372/cm.
[a] D= +72° (CHCI3, c=0, 98, 25 °C) . N° lm-5 CDCI3 300 MHz 1, 09-2,20 (14H, m) , 2,32(2H, t, J=7,2 Hz), 2,63(1H, m) , 3,63(3H, s), 3,92(1H, m) , 5,31-5,51(2H, m) , 6,35(1H, d, J=7, 0 Hz), 7,51-7,60 (3H, m) , 7, 92-7, 97(6H, m) . IV (CHCI3) : 3436, 3008, 2946, 2875, 1727, 1652, 1608(w), 1515, 1484/cm.
[a] D= +82° (CHCI3, c=0, 99, 25 °C) . N° lm-6 CDCI3 300 MHz 1, 09-2,23(14H, m) , 2,37(2H, t, J=7,2 Hz), 2,60(1H, m) , 3, 92 (1H, m) , 5, 30-5, 49 (2H, m) , 6,32(1H, d, J=7,4 Hz), 7,51-7,55 (3H, m), 7,85-7, 98 (6H, m) . IV (CHCI3) : 3436, 3010, 2950, 2875, 2670, 1727, 1715(sh) , 1650, 1605(w), 1515, 1484/cm.
[a]D= +84° (CHCI3, c=l, 54, 25 °C) . 55 N° lm-7 CDCI3 300 ΜΗζ 1, 03-2,18(14Η, m) , 2,32(2Η, t, J=7,4 Hz), 2,59(1H, m) , 3, 64 (3H, s), 3, 8 9 (1H, m) , 5,29-5, 49 (2H, m) , 6,16(1H, d, J=7,8
Hz), 6, 98-7,06 (4H, m), 7,14-7,20(1H, m), 7,34-7,41(2H, m), 7,73-7,78(2H, m). IV (CHCI3) : 3438, 3008, 2946, 2868, 1727, 1648, 1610, 1586, 1519, 1485/cm.
[a] D= +54° (CHCI3, c=l, 2 9, 25 °C) . N° lm-8 CDCI3 300 MHz 1, 06-2,21(14H, m) , 2,36(2H, t, J=7,5 Hz), 2,58(1H, m) , 3,8 8 (1H, m) , 5,31-5, 46 (2H, m) , 6,17(1H, d, J=6,9 Hz), 6, 99-7, 05(4H, m) , 7,15-7,21(H, m) , 7,36-7,41(2H, m) , 7,72-7,75(2H, m). IV (CHCI3) : 3436, 3010, 2948, 2868, 2675, 1730 (sh), 1709, 1647, 1608, 1586, 1520, 1485/cm.
[a] D= +56° (CHCI3, c=0, 97, 25 °C) . N° lm-9 CDCI3 300 MHz 1, 05-2,18(14H, m), 2,29-2,34(5H, m), 2,59(1H, m), 3,64(3H, s), 3,89(1H, m) , 5, 32-5, 46(2H, m) , 6,16(1H, d, J=7,5 Hz), 7,00-7,11(6H, m), 7,74-7,77 (2H, m) . IV (CHCI3) : 3440, 3010, 2946, 2868, 1729, 1649, 1595, 1519, 1488/cm.
[a] D= +47° (CHCI3, c=0, 82, 25°C.). N° lm-10 56 CDC13 300 MHz 1, 04-2,20(14H, m), 2,31-2,39 (5H, m), 2,57(1H, m) 3,87(1H, m) , 5,28-5, 47(2H, m) , 6,17(1H, d, J=7,0 Hz) 6,99-7,12(6H, m), 7,72-7,76(2H, m). IV (CHC13) : 3674, 3572, 3438, 3010, 2948, 2868, 2626 1748, 1710, 1648, 1615, 1520, 1489/cm.
[a] D= +51° (CHCI3, c=0, 91, 25 °C) . N° lm-11 CDCI3 300 MHz 1,04-2,16(14H, m) , 2,31(2H, t, J=7,2 Hz), 2,59(1H, m) 3, 63 (1H, m) , 5, 29-5, 49 (2H, m) , 6,24(H, d, J=7,4 Hz) 6,54(H, s), 6, 83-6, 93(6H, m), 7, 69-7,73(2H, m) . IV (CHCI3) : 3674, 3588, 3438, 3296, 3010, 2946, 2868 1725, 1646, 1603, 1520, 1504, 1489/cm.
[a] D= +51° (CHCI3, c=0, 91, 25 °C) . N° lm-12 CDC13 300 MHz 1,04 -2,21 (14H, m) , 2,33 (2H, t, J=8,0 Hz) , 2,56 (1H, m) 3,87 (1H, m) , 5,28-5,48(2H, m) , 6,2 3(1H, d, NI ix! 0 00 II >X> 6,75 (1H, m) , 6, 87-6, 94 ( 6H, m) , 7, 66-7,71(2H, m), 9,63 (1H s 1) . IV (CHCI3) : 3674, 3582, 3436, 3275, 3010, 2950, 2868 2675, 1727, 1710(sh), 1643, 1603, 1522, 1504, 1490/cm.
[a] D= +30° (CHC13, c=0, 97, 25 °C) . N° lm-13 CDCI3 300 MHz 1,01-2,18(14H, m) , 2,31(2H, t, J=7,4 Hz), 2,58(1H, m) , 3,63(3H, s), 3,82(3Η, s) , 3,89(1Η, m) , 5,29-5,48(2Η, m) , 6,14 (1Η, d, J=7,Ο Ηζ), 6, 88-7, 02 ( 6Η, m), 7,70-7,74 (2Η, m) . IV (CHC13) : 3442, 3402, 3004, 2946, 2868, 1727, 1648, 1600, 1518, 1499/cm.
[α] D= +42° (CHCI3, c=l, 82, 26 °C) . Ν° lm-14 CDCI3 300 ΜΗζ 1, 06-2,21(14Η, m) , 2,35(2Η, t, J=7,2 Hz), 2,55(1Η, m) , 3,82(3Η, s) , 3, 8 8(1Η, m) , 5,27-5,46 (2Η, m) , 6,16(1Η, d, J=7,2 Hz), 6, 88-7, 02(6Η, m) , 7, 68-7,73(2Η, m) . IV (CHCI3) : 3438, 3012, 2948, 2870, 2650, 1730(sh), 1709, 1647, 1615(sh), 1601, 1519, 1492/cm.
[α]D= +64° (CHCI3, c=0,7 0, 25 °C) . N° lm-15 CDCI3 300 MHz 1,05-2,20(14H, m), 2,29-2,36(5H, m), 2,62(1H, m), 3, 63(3H, s), 3, 92(1H, m) , 5, 30-5, 50 (2H, m) , 6,25(1H, d, J=7,2 Hz), 7,16-7,21 (2H, m) , 7,59-7, 64(4H, m) , 7, 83-7, 87(2H, m) . IV (CHCI3) : 3446, 3010, 2946, 2868, 1745(sh), 1728, 1650, 1615, 1525, 1507, 1486/cm.
[a] D= +65,0° (CHCI3, c=l, 02, 23 °C) . N° lm-16 CDCI3 300 MHz 1, 08-2,21(14H, m), 2,34-2,40(5H, m), 2,59(1H, m), 3,90(1H, m) , 5, 29-5, 48 (2)H, m) , 6,29(1H, d, J=7,0 Hz), 7,18 (2H, d, J=8, 6 Hz), 7,58-7, 64 (4H, m) , 7,83(2H, d, J=8,2 Hz) . 58 IV (CHCls) : 3438, 3012, 2948, 2870, 2622, 1749, 1710, 1649, 1610, 1526, 1508, 1487/cm.
[α] D= +66° (CHC13, c=l,21, 24 °C) . N° lm-17 CDCI3 300 MHz 1, 06-2,19 (14H, m) , 2,32(2H, t, J=7,2 Hz), 2,62(1H, m) , 3,63 (3H, s), 3, 93(1H, m) , 5,30-5,50 (2H, m) , 6,32(1H, d, J=7,6
Hz), 6,41 (1H, s), 6, 94 (2H, d, J=9, 0 Hz), 7,47(2H, d, J=9, 0
Hz), 7,58 (2H, d, J=8, 6 Hz), 7,81(2H, d, J=8,6 Hz). IV (CHCI3) : 3580, 3434, 3284, 3010, 2946, 2868, 1726, 1646, 1606, 1528, 1490/cm.
[a] D= +62,4° (CHCI3, c=l,01, 23 °C) . N° lm-18 CDCI3+CD3OD 300 MHz 1, 11-2,18 (14H, m), 2,32(2H, t, J=7,4 Hz), 2,59(1H, m) , 3,88 (1H, m) , 5, 30-5, 49 (2H, m) , 6,55(1H, d, J=7,0 Hz), 6, 92 (2H, d, J=8,6 Hz), 7,47 (2H, d, J=8,6 Hz), 7,59(2H, d, J=8,6 Hz), 7,79 (2H, d, J=8,2 Hz) . IV (Nujol) : 3398, 3175, 2725, 1696, 1635, 1601, 1531, 1510/cm.
[a] D= +99,5° (CH3OH, c=l,011, 25 °C) . N° lm-19 CDCI3 300 MHz 1, 05-2,20(14H, m) , 2,32(2H, t, J=7,4 Hz), 2,61(1H, m) , 3,63(3H, s), 3,83(3H, s), 3,94(1H, m) , 5, 30-5, 50 (2H, m) , 6,24 (1H, d, J=7,0 Hz), 6,99(2H, d, J=8,6 Hz), 7,63-7,63 (4H, m), 7,82(2H, d, J=8,6 Hz). 59 IV (CHC13) : 3440, 3006, 2946, 2875, 1726, 1649, 1606 1527, 1510, 1489/cm.
[α] D= +68° (CHC13, c=0, 8 8, 26 °C) . N° lm-20 CDCI3 300 MHz 1, 09-2,20(14H, m) , 2,35(2H, t, J=7,3 Hz), 2,58(1H, m) , 3,85 (3H, s), 3,8 9 (1H, m) 5,28-5,48(2H, m) , 6,35(1H, d, J=7,2
Hz), 6,98(2H, d, J=8,8 Hz), 7,51-7,61(4H, m), 7,81(2H, d, J=8,4 Hz), 8,34(1H, s 1) . IV (CHCI3) : 3446, 3012, 2952, 2881, 2640, 1730(sh), 1707, 1647, 1606, 1527, 1510, 1489/cm.
[a]D= +83° (CHCI3, c=l, 00, 25 °C) . N° lm-21 CDCI3 300 MHz 1,05-2,14(14H, m) , 2,37(2H, t, J=7,2 Hz) , 2,51 (1H, m) 3,81(1H, m) , 5, 34-5, 46 (2H, m) , 6,11(1H, d, J=7,5 Hz) 7,33-7,48(3H, m), 7,53-7,55(2H, m) . IV (CHCI3): 3420, 3250, 3008, 2948, 2870, 2660, 2210 1735(sh), 1705, 1645, 1503, 1441, 1409/cm.
[a] D= +59,2+1,0° (CHCI3, c=l, 023, 22 °C) . N° lm-22 CDCI3 300 MHz 1, 05-2,17(14H, m) , 2,37(2H, t, J=7,2 Hz), 2,52(1H, m) , 3,82(1H, m) , 5,32-5,47 (2H, m) , 6,20(1H, d, J=7,6 Hz), 7,38-7,53(3H, m) , 7,58-7, 61(6H, m) , 9,11(1H, s 1). IV (CHCI3) : 3420, 3250, 3010, 2984, 2870, 2675, 2208, 60 1730(sh), 1705, 1640, 1500, 1406/cm.
[α] D= +57,4° (CHC13, c=l, 83, 23 °C) . N° lm-23 CDCI3 300 MHz 1, 05-2,18 (14H, m) , 2,31(2H, t, J=7,5 Hz), 2,60(1H, m) , 3,63(3H, s) , 3,90(1H, m) , 5,32-5,47 (2H, m) , 6,22(1H, d, J=6, 9
Hz), 7,40-7,49(3H, m), 7,76-7,79 (2H, m) . IV (CHCI3) : 3438, 3008, 2946, 2868, 1727, 1651, 1603, 1585, 1521, 1484/cm.
[a] D= +52° (CHCI3, c=l, 4 9, 25 °C) . N° lm-24 CDCI3 300 MHz 1,05-2,21(14H, m) , 2,36(2H, t, J=7,2 Hz), 2,57(1H, m) , 3,8 9 (1H, m) , 5,28-5,47(2H, m) , 6,22(1H, d, J=7,0 Hz), 7,39-7,55(3H, m), 7,73-7,79(2H, m). IV (CHCI3) : 3676, 3572, 3436, 3010, 2948, 2875, 1730(sh), 1709, 1650, 1600, 1580, 1514, 1484/cm.
[a] D= +57° (CHCI3, c=0, 97, 26 °C) . N° lm-25 CDCI3 300 MHz 1, 04-2,18(14H, m), 2,28-2,35(5H, m), 2,59(1H, m), 3,62(3H, s), 3,8 8(1H, m) , 5,29-5,49 (2H, m) , 6,20(1H, d, J=7,2
Hz), 7,15 (2H, d, J=9, 0 Hz), 7,80(2H, d, J=8,8 Hz). IV (CHCI3) : 3436, 3010, 2946, 2868, 1752, 1727, 1653, 1602, 1519, 1491/cm.
[a]D= +53° (CHCI3, c=l, 63, 25 °C) . 61 N° lm-26 CDC13 300 ΜΗζ 1, 05-2,19(14Η, m), 2,32-2,38(5Η, m), 2,56(1Η, m), 3, 8 8 (1Η, m) , 5,29-5,47 (2Η, m) , 6,25(1Η, d, J=7,4 Hz), 7,15(2Η, d, J=9,0 Hz), 7,7 8 (2H, d, J=8,6 Hz). IV (CHCI3) : 3434, 3016, 3006, 2948, 2880, 2622, 1752, 1730 (sh), 1710, 1651, 1605, 1520, 1492/cm.
[a] D= +58° (CHCI3, c=3, 68, 24 °C) . N° lm-27 CDCI3 300 MHz 1, 05-2,16(14H, m) , 2,30 (2H, t, J=7,5 Hz), 2,57(1H, 3,62 (3H, s), 3,87(1H, m), 5,27-5, 47(2H, m) , 6, 32(1H, J=7,4 Hz), 6,85(2H, d, J=8,6 Hz), 7, 62(2H, d, V£> 00 II •d 8,35(1H, s) . IV (CHCI3) : 3580, 3450, 3216, 3010, 2946, 2868, 1726, 1640, 1608, 1584, 1528, 1496/cm.
[a] D= +56,2° (CHCI3, c=0,713, 23 °C) . N° lm-28 CDCI3 200 MHz 1,10-2,25 (14H, m) , 2,32(2H, t, J=7,2 Hz), 2,55(1H, s 1) , 3, 82-3, 93(1H, m), 5, 27-5, 47 (2H, m), 6,25(1H, d, J=7,4 Hz), 6,86 (2H, d, J=8, 6 Hz), 7,62(2H, d, J=8,6 Hz). IV (CHCI3) : 3438, 3242, 2675, 1730 (sh), 1708, 1639, 1607, 1585/cm. 62 N° lm-29 CDC13 300 ΜΗζ 1,05 -2,18(14H, m) , 2,31(2H, t, J=7,4 Hz), 2,58 (1H, m) 3, 64(3H, s), 3,85(3H, s), 3,89(1H, m) , 5, 29-5, 48 (2H, m) 6,14(1H, d, J=6,6 Hz), 6, 92(2H, d, O II •d Hz), 7,74(2H, d N O II • IV (CHCI3) : 3445, 3008, 2946, 2868, 1727, 1646, 1606 1578, 1523, 1493/cm.
[α] D= +53° (CHCI3, c=2, 03, 24 °C) . N° lm-30 CDCI3 300 MHz 1,04-2,21(14H, m) , 2,36(2H, t, J=7,3 Hz), 2,56(1H, m) , 3,85(3H, s), 3, 88(1H, m) , 5, 27-5, 46 (2H, m) , 6,15(1H, d, J=7,2 Hz), 6, 92(2H, d, J=8,6 Hz), 7,73(2H, d, J=8,6 Hz). IV (CHCI3): 3440, 3010, 2950, 2870, 2645, 1727, 1710(sh), 1646, 1606, 1575, 1524, 1494/cm.
[a]D= +62° (CHCI3, c=l,10, 24 °C) . N° lm-31 CDCI3+CD3OD 300 MHz 1, 16-2,20(14H, m) , 2,31(2H, t, J=7,2 Hz), 2,59(1H, m) , 3,85(1H, m), 5, 31-5,51(2H, m) , 7, 13-7,21(1H, m) , 7,31-7,42(2H, m) , 7, 68-7, 93(6H, m) . IV (Nujol): 3344, 3175, 2715, 2675, 1699, 1631, 1566/cm.
[a] D= +67° (CH3OH, c=l,01, 24 °C) . N° lm-32 CDCI3 200 MHz 63 1,09-2,23(14Η, m), 2,33(2H, t, J=7,l Hz), 2,57(1H, s 1), 3,40-3,93(9H, m), 4,41(1H, s 1), 5,29-5,48(2H, m), 6,44(1H, d, J=7,4 Hz), 7,43 (2H, d, J=8,2 Hz), 7,80(2H, d, J=7,8 Hz). IV (CHC13) : 3434, 3354, 1726, 1720 (sh), 1660(sh), 1626/cm. N° lm-33 CDCI3 200 MHz 1, 14-2,25(14H, m) , 2,37(2H, t, J=7,3 Hz), 2,64(1H, s 1), 3, 93-4,01(1H, m), 5,30-5,51 (2H, m), 6,47(1H, d, J=7,4 Hz), 7, 63-7,74(2H, m) , 7,79(2H, s) , 7, 89-7, 93(1H, m) , 8,00(1H, dd, J=2,3, 1,0 Hz), 8,30(1H, d, J=1,0 Hz), 8 , 65-8,73(2H, m) . IV (CHCI3) : 3450, 2675, 1728, 1707, 1649, 1528, 1509/cm.
[a]D= +82,8+1,2° (CHC13, c=l,01, 23 °C) . N° 2a-l [a] D= +69,0° (MeOH, c=l,01, 25 °C) N° 2a-2 CDCI3 300 MHz 0,99(1H, d, J=10,2 Hz), 1,15 e 1,24 (cada 3H, cada s) , 1,50-2,50 (14H, m) , 4,30(1H, m) , 5,35-5,52 (2H, m) , 6,32(1H, d, J=8,7 Hz), 7,36-7,49 (3H, m) , 7,58-7, 62 (2H, m) , 7,66 e 7,80(cada 2H, cada d, J=8,7 Hz). IV (CHCI3) : 3116, 3014, 2925, 2870, 2663, 1708, 1651, 1610, 1524, 1504, 1484, 1472/cm.
[a] D= +64,1° (MeOH, c=l, 02, 25 °C) . N° 2a-3 [a] D= +76,6° (MeOH, c=l,18, 26 °C) . 64 N° 2a-4 CDC13 300 ΜΗζ 0, 99 (1Η, d, J=10,2 Hz), 1,15 e 1,25 (cada 3H, cada s) , 1, 64-2,51(14H, m) , 4,31(1H, m) , 5,36-5,53 (2H, m) , 6,33(1H, d, J=8,4z), 7,50-7,56 (3H, m) , 7, 85-7, 98 ( 6H, m) . IV (CHCI3) : 3515, 3452, 3014, 2925, 2870, 1740, 1708, 1654, 1517, 1486, 1470/cm.
[a] D= +79,5° (MeOH, c=l,18, 22 °C) . N° 2a-5 CD3OD 300 MHz 0,98(1H, d, J=9, 9 Hz), 1,18 e 1,25 (cada 3H, cada s) , 1,56-1,71(3H, m), 1, 98-2,40 (11H, m), 4,17(1H, m) , 5, 41-5,52(2H, m) , 7,52-7,61(3H, m), 7,91-8,01(6H, m) . IV (KBr): 3416, 3063, 2983, 2921, 2869, 1704, 1643, 1566, 1518, 1488, 1408/cm.
[a] D= +62,0° (MeOH, c=l, 00, 25 °C) . N° 2a-6 [a] D= +64,1° (MeOH, c=l,01, 25 °C) . N° 2a-7 [a] D= +65,3° (MeOH, c=0, 99, 25 °C) . N° 2a-8 [a] D= +74,0° (MeOH, c=l,01, 25 °C) . N° 2a-9 65 [α] D= +71,0° (MeOH, c=l,10, 25 °C) . N° 2a-l0 [a] D= +74,7° (MeOH, c=l, 0 0, 25 °C) . N° 2a-l1 [a] D= +72,1° (MeOH, c=l, 00, 25 °C) . N° 2a-12 [a] D= +53,1° (CHC13, c=l, 01, 26 °C) .
p.f. 155,0-156,0 °C N° 2a-13 CDCI3 300 MHz 3H, cada s) , , 6,4 4 (1H, d, J=8,7 Hz), 1713, 1652, 0,98(1H, d, J=10,2 Hz), 1,18 e 1,25(cada 1, 63-2,40(14H, m) , 4,30(1H, m) , 5,46-5,58(2H, m) J=8,4 Hz), 7,49 e 7,77 (cada 2H, cada d, 7,54 (1H, s) . IV (CHCI3) : 3689, 3378, 3028, 3014, 2924, 1602, 1522, 1496/cm.
[a] D= +78,3° (MeOH, c=0, 84, 25 °C) . p.f. 205,0-206,0 °C N° 2a-14 [a] D= +72,5° (MeOH, c=l, 07, 25 °C) . N° 2a-15 66 CDC13 300 MHz 0, 99 (1H, d, J=9, 9 Hz), 1,14 e 1,24 (cada 3H, cada s) , 1,55-2,44(14H, m) , 4,27(1H, m) , 5, 30-5, 50(2H, m) , 6,29(1H, d, J=9,0 Hz), 7,11 e 7,20 (cada 1H, cada d, J=16,2 Hz), 7,29-7,55(5H, m), 7,57 e 7,72(cada 2H, cada d, J=8,7 Hz). IV (CHC13) : 3453, 3083, 3022, 3013, 2925, 2870, 1708, 1650, 1607, 1560, 1522, 1496/cm.
[a]D= +72,3° (MeOH, c=l,00, 27 °C). p.f. 115,0-117,0 °C N° 2a-l6 CDCI3 300 MHz 0,92 (1H, d, J=10,2 Hz), 1,11 e l,23(cada 3H, cada s) , 1.50- 2,48(14H, m) , 3,62(3H, s) , 4,29(1H, m) , 5, 30-5, 50(2H, m) , 6,20(1H, d, J=8,7 Hz), 6,59 e 6, 68 (cada 1H, cada d, J=12,3 Hz), 7,23(5H, s), 7,29 e 7,59(cada 2H, cada d, J=8,l Hz). IV (CHCI3) : 3453, 3024, 3016, 2924, 2870, 1730, 1651, 1607, 1520, 1495/cm.
[a] D= +56,8° (MeOH, c=l, 04, 24 °C) . N° 2a-17 CDCI3 300 MHz 0, 97 (1H, d, J=10,2 Hz), 1,11 e l,23(cada 3H, cada s) , 1.50- 2,38(14H, m) , 4,26(1H, m) , 5,30-5,50(2H, m) , 6,23(1H, d, J=8,4 Hz), 6,59 e 6,70 (cada 1H, cada d, J=12,3 Hz), 7,23(5H, s), 7,30 e 7,57(cada 2H, cada d, J=8,7 Hz). IV (CHCI3) : 3452, 3081, 3019, 3014, 2925, 2870, 2665, 1708, 1650, 1607, 1521, 1495/cm.
[a] D= +61,6° (MeOH, c=l, 00, 27 °C) . N° 2a-18 67 CDC13 300 MHz 0, 97 (1H, d, J=10,2 Hz), 1,11 e 1,23 (cada 3H, cada s) , 1.50- 2,50(14H, m) , 3,61(3H, s) , 4,31(1H, m) , 5, 35-5,51(2H, m) , 6,33(1H, d, J=8,4 Hz), 7,48-7, 64 (4H, m), 7,79-7,83 (2H, m), 7,91 (1H, dt, J=1,5 e 7,8 Hz), 8,01(1H, dt, J=l,5 e 7,8 Hz), 8,13(1H, t, J=l,5 Hz). IV (CHC13) : 3450, 3026, 3013, 2925, 2870, 1730, 1659, 1600, 1510/cm.
[ α ] D= +56,0° (MeOH, c=l,01, 25 °C) . N° 2a-l9 CDCI3 300 MHz 0, 95 (1H, d, J=9, 9 Hz), 1,14 e 1,21 (cada 3H, cada s) , 1,53-2, 60(14H, m) , 4,25(1H, m) , 5, 35-5, 64(2H, m) , 7,21(1H, d, J=7, 8 Hz), 7,49-7, 68 (4H, m) , 7,76-7,84(3H, m) , 8,25(1H, m) , 8,43(1H, m). IV (CHCI3) : 3382, 3196, 3025, 3015, 2925, 2870, 1725, 1652, 1599, 1577, 1521/cm.
[a] D= +55,9° (MeOH, c=l, 00, 25 °C) . N° 2a-20 CDCI3 300 MHz 0, 98 (1H, d, J=10,2 Hz), 1,13 e 1,24 (cada 3H, cada s) , 1.50- 2,50(14H, m) , 3,62(3H, s) , 4,31(1H, m) , 5, 35-5,51(2H, m) , 6,24 (1H, d, J=8,4 Hz), 7,40-7,52(3H, m) , 7,71-7,76(2H, m) . IV (CHCI3) : 3453, 3025, 3013, 2925, 2870, 1730, 1753, 1579, 1514, 1486/cm.
[a] D= +61,2° (MeOH, c=l, 04, 25 °C) . N° 2a-21 68 CDC13 300 MHz 0,98(1H, d, J=10,2 Hz), 1,13 e 1,23 (cada 3H, cada s) , 1.52- 2,50(14H, m) , 4,28(1H, m) , 5, 34-5,51(2H, m) , 6,27(1H, d, J=8,7 Hz), 7,41-7,53(3H, m), 7,71-7,74(2H, m) . IV (CHC13) : 3452, 3063, 3027, 3014, 2925, 2871, 1708, 1652, 1578, 1515, 1486/cm.
[a] D= +62,0° (MeOH, c=l,01, 27 °C) . N° 2a-22 ds-DMSO 300 MHz 0, 8 6 (1H, d, J=9, 9 Hz), 1,10 e 1,16 (cada 3H, cada s) , 1,42-1,52(3H, m) , 1, 85-2,46(11H, m) , 3,98(1H, m) , 5,32-5,43 (2H, m) , 7,41 (3H, m) , 7,88(2H, d, J=6, 6 Hz), 8,19(1H, d, J=6,6 Hz). IV (KBr): 3367, 3060, 2984, 2922, 2868, 1634, 1563, 1529, 1487/cm.
[a] D= +47,7(MeOH, c=l, 00, 25°C.)· N° 2a-23 [a] D= +62,7° (MeOH, c=l,01, 27 °C) . N° 2a-24 CDCI3 300 MHz 0, 99 (1H, d, J=10,2 Hz), 1,14 e l,25(cada 3H, cada s) , 1.52- 2,50(14H, m) , 4,31(1H, m) , 5,36-5,52(2H, m) , 6,34(1H, d, J=8,4 Hz), 7,47-7,52 (2H, m) , 7,59-7, 64 (1H, m) , 7,78-7,83 (6H, m) . IV (CHCI3): 3449, 3027, 3013, 2925, 2869, 1708, 1656, 1599, 1518, 1493/cm.
[a] D= +63,1° (MeOH, c=l, 00, 25 °C) . 69 N° 2a-25 [α] D= +35,1° (MeOH, c=l, 00, 25 °C) . N° 2a-26 [a] D= +35,5° (MeOH, c=l, 02, 25 °C) . N° 2a-27 CDC13 300 MHz 0,97(1H, d, J=10,2 Hz), 1,12 e 1,23 (cada 3H, cada s) , 1.52- 2,50(14H, m), 3,63(3H, s), 4,29(1H, m) , 5,36-5,51 (2H, m), 6,18(1H, d, J=8,4 Hz), 7,01 e 7,71 (cada 2H, cada d, J=8,7 Hz), 6,98-7,05(2H, m), 7,16(1H, t, J=7,5 Hz), 7,34-7,41 (2H, m). IV (CHCI3): 3455, 3024, 3016, 2924, 2870, 1730, 1651, 1588, 1520, 1487/cm.
[a] D= +56,4° (MeOH, c=l,01, 25 °C) . N° 2a-28 CDCI3 300 MHz 0,98(1H, d, J=10,2 Hz), 1,12 e 1,23 (cada 3H, cada s) , 1.52- 2,50(14H, m), 4,26(1H, m), 5,34-5,51 (2H, m), 6,20(1H, d, J=9,0 Hz), 7,01 e 7,70(cada 2H, cada d, J=9,0 Hz,), 6,98-7,15(2H, m) , 7,17(1H, t, J=7,5 Hz), 7,34-7,40 (2H, m) . IV (CHCI3) : 3454, 3031, 3018, 2925, 2870, 1708, 1650, 1588, 1523, 1487/cm.
[a] D= +56,2° (MeOH, c=l, 00, 25°C.). N° 2a-29 70 [a] D= +53,0 0 (MeOH, c=l, 03, 25 °C) . N° 2a-30 CDC13 300 MHz 0,97(1H, d, J=10,2 Hz), 1,10 e 1,23 (cada 3H, cada s) , 1,52-2,50(14H, m) , 4,25(1H, m) , 5,30-5,50(2H, m) , 6,23(1H, d, J=8,7 Hz), 6,36(1H, s) , 7,2 6-7,3 9 (1 OH, m) , 7,60 e 7,68 (cada 2H, cada d, J=8,4 Hz,). IV (CHC13) : 3451, 3088, 3064, 3029, 3014, 2925, 2869, 1707, 1652, 1522, 1495/cm. [a] D= +54,2° (MeOH, c=l,00, 25 °C). N° 2a-31 CDCI3 300 MHz 0,98(1H, d, J=10,2 Hz), 1,14 e 1,24 (cada 3H, cada s) , 1,50-2,50(14H, m), 3,63(3H, s), 4,31(1H, m) , 5,30-5,50 (2H, m), 6,2 6 (1H, d, J=8,4 Hz), 6,90(1H, t, J=7,4 Hz), 7,13(1H, d, J=8,7 Hz), 7,29(2H, t, J=8,0 Hz), 7,67-7,75(5H, m), 7,82 (1H, s) . IV (Nujol) : 1495/cm. 3380, 3244, 1723, 1638, 1601, 1578, 1535, [a] D= +73,6° (MeOH, c=0,50, 26 °C).
p.f. 133,0-134,0 °C N° 2a-32 [a] D= +56,1° (MeOH, c=l, 02, 26 °C) . N° 2a-33 CDCI3 300 MHz 71 0, 95 (1Η, d, J=10,2 Hz), 1,10 e l,21(cada 3H, cada s) , 1,50-2,50(14H, m), 4,25(1H, m) , 5,13(2H, s), 5,30-5,70(3H, m), 6,41(1H, d, J=8,2 Hz), 6,89(1H, s), 7,09(1H, s), 7,17 e 7,72(cada 2H, cada d, J=8,2 Hz), 7,62(1H, s). IV (CHC13) : 3450, 3125, 3031, 3013, 2925, 2870, 2467, 1917, 1708, 1654, 1615, 1575, 1523, 1497/cm.
[a] D= +55,2° (MeOH, c=l,01, 26 °C) . N° 2a-34 [a] D= +72,9° (MeOH, c=l, 03, 25 °C) . N° 2a-35 CDCI3 300 MHz 0, 98 (1H, d, J=10,2 Hz), 1,13 e l,24(cada 3H, cada s) , 1,52-2,48(14H, m) , 4,28(1H, m) , 5, 35-5,51(2H, m) , 6,28(1H, d, J=8,7 Hz), 7,34-7,37(3H, m) , 7,52-7,55(2H, m) , 7,58 e 7,71(cada 2H, cada d, J=8,7 Hz). IV (CHCI3) : 3515, 3452, 3030, 3012, 2925, 2870, 1739 1708, 1652, 1607, 1555, 1521, 1497/cm.
[a] D= +74,3° (MeOH, c=l,01, 25 °C) . N° 2a-36 [a] D= +23,4° (MeOH, c=l, 07, 25 °C) . N° 2a-37 CDCI3 300 MHz 0, 83 (1H, d, J=10,5 Hz), 0,95 e 1,18 (cada 3H, cada s) 1,44-2,46(14H, m), 3,92(1H, m), 5, 34-5, 52(3H, m) 7,26-7,54 (9H, m) , 7,62(1H, s) . IV (CHCI3) : 3432, 3310, 3189, 3023, 3014, 2924, 2870 72 1704, 1610, 1594, [ α ] D= +25,3° Ν° 2a-38 [α] D= +70,9° Ν° 2a-39 [α] D= +70,6° Ν° 2a-40 [α] D= +74,7° Ν° 2a-41 [α] D= +72,10 Ν° 2a-42 [α] D= +69,2° Ν° 2a-43 [α] D= +70,8° Ν° 2a-44 [α] D= +60,4° Ν° 2a-45 1523, 1487/cm. (MeOH, c=l,00, 26 °C) (MeOH, c=l,02, 25 °C) (MeOH, c=l,01, 25 °C) (MeOH, c=l,00, 25 °C) (MeOH, c=l,01, 24 °C) (MeOH, c=l,00, 25 °C) (MeOH, c=l,00, 25 °C) (MeOH, c=l,00, 26 °C) 73 CDC13 300 MHz 0,97(1H, d, J=9, 9 Hz), 1,13 e 1,23 (cada 3H, cada s) , 1,55-2,52(14H, m) , 4,29(1H, m) , 5,34-5,54(2H, m) , 6,33(1H, d, J=9,0 Hz), 7, 10(1H, t, J=7,4 Hz), 7,34(2H, t, J=7,4 Hz), 7,52(2H, m) , 7,68 e 7,75(cada 2H, cada d, J=8,4 Hz), 7,80(1H, s), 8,10 (1H, s), 10,09 (1H, s) . IV (CHC13) : 3393, 3195, 3093, 3033, 3013, 2925, 2870, 1698, 1656, 1598, 1537, 1498/cm.
[a] D= +59,4° (MeOH, c=l,01, 24 °C) . N° 2a-46 [a] D= +63,5° (MeOH, c=l, 00, 25 °C) . N° 2a-47 CDCI3 300 MHz 0,97(1H, d, J=9, 9 Hz), 1,12 e 1,23 (cada 3H, cada s) , 1,54-2,48(14H, m) , 4,29(1H, m) , 5,35-5,52(2H, m) , 6,32(1H, d, <d II co 7 Hz), 7,26 (1H, m) , 7,41 (2H, t, J=7,8 Hz), 7,64 (2H, d, II ^1 5 Hz), 7,73 e 7,77(cada 2H, cada d, J=8,4 Hz), 7,95 (1H, s), 9,20(1H, s) , 10,38(1H, s) . IV (CHCI3) : 3450, 3339, 3003, 2992, 2925, 2870, 1706, 1653, 1596, 1523, 1495/cm.
[a] D= +63,3° (MeOH, c=l, 00, 25 °C) . N° 2a-48 [a] D= +63,8° (MeOH, c=l, 00, 24 °C) . N° 2a-49 CDCI3 300 MHz 1,00(1H, d, J=10,5 Hz), 1,17 e l,26(cada 3H, cada s) , 1,55-2,52(14H, m) , 4,34(1H, m) , 5,36-5,54 (2H, m) , 6,35(1H, d, J=9, 0 Hz), 7,50-7, 62 (3H, m) , 7,90 e 3 (cada 2H, cada d, J=8,4 Hz), 8,21 (2H, m) . IV (CHC13) : 3451, 3029, 3022, 3016, 2925, 2870, 1708, 1655, 1542, 1508, 1498, 1471, 1459/cm.
[a] D= +63,5° (MeOH, c=l, 02, 250 °C) .
p.f. 135,0-137,0 °C N° 2a-50 [a] D= +68,9° (MeOH, c=l, 02, 24 °C) . N° 2a-51 de-DMSO 300 MHz 0,87(1H, d, J=9, 9 Hz), 1,10 e 1,17 (cada 3H, cada s) , 1,40-1,60(3H, m), 1,90-2,40(11H, m), 3,98(1H, m), 5,35-5,46 (2H, m) , 7,64(1H, s) , 7,65 e 7,91(cada 2H, cada d, J=8,7 Hz), 8, 0 6 (1H, d, J=6,0 Hz), 9,32(1H, s 1). IV (KBr): 3385, 2962, 1734, 1707, 1632, 1529, 1498/cm.
[a] D= +68,4° (MeOH, c=l,01, 24 °C) . N° 2a-52 [a] D= +76,2° (MeOH, c=l,01, 24 °C) . N° 2a-53 [a] D= +73,9° (MeOH, c=l, 02, 24 °C) . N° 2a-54 75 [α] D= +68,1° (MeOH, c=l, 00, 24 °C) . N° 2a-55 [a] D= +67,8° (MeOH, c=l, 00, 24 °C) . N° 2a-56 [a] D= +65,4° (MeOH, c=l, 03, 25 °C) . N° 2a-57 [a] D= +63,4° (MeOH, c=l,01, 24 °C) . N° 2a-58 [0793] [a] D= +66,6° (MeOH, c=l,01, 24 °C) . N° 2a-59 [a] D= +65,5° (MeOH, c=l, 00, 24 °C) . N° 2a-60 [a] D= +60,9° (MeOH, c=l, 02, 25 °C) . N° 2a-61 CDC13 300 MHz cada s) , ,28(1H, d, , 7,12 (2H, 8,47 (2H, 0, 97 (1H, d, J=10, 0 Hz), 1,10 e l,22(cada 3H, 1,50-2,50(14H, m) , 4,26(1H, m) , 5,30-5,54 (2H, m) , 6 J=8,6 Hz), 6,60 e 6,82 (cada 1H, cada d, J=12,4 Hz, ) d, J=6,0 Hz), 7,25 e 7,62(cada 2H, cada d, J=8,6 Hz), 76 d, J=6,0 Hz) . IV (CHC13): 3452, 3027, 3019, 3013, 2925, 2870, 2480, 1708, 1651, 1606, 1520, 1494/cm.
[a] D= +61,6° (MeOH, c=l,01, 25 °C) . N° 2a-62 [a] D= +72,0° (MeOH, c=0, 93, 25°C) . N° 2a-63 CDCI3 300 MHz 0, 99 (1H, d, J=10,2 Hz), 1,14 e l,24(cada 3H, cada s) , 1,50-2,50(14H, m) , 4,29(1H, m) , 5, 36-5, 55 (2H, m) , 6,35(1H, d, J=9,l Hz), 7,04 e 7,27(cada 1H, cada d, J=16,5 Hz), 7,37(2H, d, J=6, 6 Hz), 7,56 e 7,76(cada 2H, cada d, J=8,4 Hz), 8,57(2H, d, J=6,6 Hz). IV (CHCI3) : 3452, 3024, 3018, 3014, 2925, 2870, 2470, 1933, 1708, 1652, 1605, 1521, 1496/cm.
[a] D= +69,2° (MeOH, c=l,01, 25 °C) . N° 2a-64 [a] D= +56,9° (MeOH, c=l, 24, 25 °C) . N° 2a-65 CDCI3 300 MHz 0, 98 (1H, d, J=10,5 Hz), 1,12 e l,23(cada 3H, cada s) , 1,54-2,46(14H, m), 4,27(1H, m) , 5,23(2H, s), 5,34-5,52(2H, m), 6,26 (1H, d, J=8,4 Hz), 7,32-7,45(5H, m), 7,64 e 7,71(cada 2H, cada d, J=8,4 Hz), 8,15(1H, s) . IV (CHCI3): 3452, 3088, 3065, 3032, 3013, 2925, 2870, 1708, 1653, 1611, 1559, 1522, 1496/cm. 77 [α] D= +61,0° (MeOH, c=0,91, 25 °C) . N° 2a-66 [a] D= +76,0° (MeOH, c=l,01, 25 °C) . N° 2a-67 CDC13 300 MHz 0,98(1H, d, J=10,4 Hz), 1,14 e l,24(cada 1.54- 2,46(14H, m) , 4,28(1H, m) , 5,32-5,53 (2H, m) J=8,6 Hz), 6,92-7,31(cada 1H, cada d, J=16,4 Hz), J=5, 8 e 3,6 Hz), 7,12(1H, d, J=3, 6 Hz), 7,24(1H, 7,51 e 7,70 (cada 2H, cada d, J=8,4 Hz). IV (CHCI3) : 3453, 3029, 3013, 2925, 2870, 1604, 1524, 1515, 1494/cm.
[a] D= +76,2° (MeOH, c=l, 00, 24 °C) . p.f. 104,0-106,0 °C N° 2a-68 [a] D= +57,7° (MeOH, c=l,01, 25 °C) . N° 2a-69 CDCI3 300 MHz 0,99 (1H, d, J=10,2 Hz), 1,14 e l,24(cada 1.54- 2,48(14H, m) , 4,28(1H, m) , 5,34-5,53 (2H, m) J=9,0 Hz), 6,54-6,74(cada 1H, cada d, J=12,0 Hz), J=4, 8 e 3,3 Hz), 6,97(1H, dd, J=3,3 e 1,2 Hz), J=4,8 e 1,2 Hz), 7,44 e 7,70(cada 2H, cada d, J=8, IV (CHCI3) : 3453, 3025, 3010, 2925, 2870, 1607, 1559, 1523, 1493/cm.
[a] D= +58,4° (MeOH, c=l, 00, 25 °C) . 3H, cada s) , , 6,27 (1H, d, 7,02 (1H, dd, d, J=5,8 Hz), 1739, 1650, 3H, cada s) , , 6,2 9 (1H, d, 7,02(1H, dd, 7,13 (1H, dd, .7 Hz) . 1708, 1650, 78 N° 2a-7Ο [α] D= +48,6° (MeOH, c=l, 00, 25 °C) . N° 2a-71 CDC13 300 MHz 0,98(lHd, J=10,2 Hz), 1,12 e 1,23(cada 3H, cada s) , 1,52-2,46(14H, m) , 2,31(3H, s), 4,26(1H, m) , 5,33-5,52 (2H, m) , 6,20(1H, d, J=9,3 Hz), 7, 02-7,11(6H, m) , 7,70(2H, d, J=9,0 Hz) . IV (CHCI3) : 3460, 3031, 3022, 3011, 2925, 2870, 1750, 1708, 1650, 1608, 1597, 1523, 1490/cm.
[a] D= +48,9° (MeOH, c=l,01, 25 °C) . N° 2a-72 [a] D= +51,2° (MeOH, c=l, 02, 25 °C) . N° 2a-73 CDCI3 300 MHz 0,97(1H, d, J=9, 9 Hz), 1,11 e 1,23 (cada 3H, cada s) , 1,54-2,48(14H, m) , 4,27(1H, m) , 5,32-5,52 (2H, m) , 6,24(1H, d, J=9, 0 Hz), 6, 83-6, 94 (6H, m) , 7,65(2H, d, J=9,0 Hz). IV (CHCI3): 3598, 3451, 3199, 3033, 3012, 2925, 2870, 1708, 1642, 1604, 1524, 1507, 1491/cm.
[a] D= +52,2° (MeOH, c=l,01, 25°C.). N° 2a-74 [a] D= +51,5° (MeOH, c=0, 92, 250°C). 79 N° 2a-75 CDC13 300 ΜΗζ 0, 97 (1Η, d, J=10,2 Hz), 1,11 e 1,23 (cada 3H, cada s) , 1,55-2,46(14H, m) , 3,82(3H, s), 4,25(1H, m) , 5,32-5,52 (2H, m), 6,19(1H, d, J=8,7 Hz), 6,89-7,01 ( 6H, m), 7, 65-7, 68 (2H, m) . IV (CHCI3) : 3450, 3025, 3008, 2925, 2870, 2837, 1741, 1649, 1612, 1521, 1505, 1490/cm.
[a] D= +51,1° (MeOH, c=l, 00, 25 °C) . N° 2a-76 [a] D= +60,4° (MeOH, c=0, 98, 25 °C) . N° 2a-77 CDCI3 300 MHz 0,99(1H, d, J=10,5 Hz), 1,15 e 1,24 (cada 3H, cada s) , 1,54-2,48(14H, m) , 2,34(3H, s), 4,29(1H, m) , 5,32-5,54(2H, m), 6,32(1H, d, J=8,4 Hz), 7,19 e 7,60 (cada 2H, cada d, J=8,4 Hz), 7,63 e 7,79(cada 2H, cada d, J=8,4 Hz). IV (CHCI3) : 3452, 302-7, 3012, 2925, 2870, 1751, 1709, 1651, 1611, 1560, 1527, 1509, 1489/cm.
[a] D= +61,2° (MeOH, c=l, 00, 25 °C) . N° 2a-78 [a] D= +67,4° (MeOH, c=l,01, 25 °C). N° 2a-79 CDCI3 300 MHz 0,99(1H, d, J=10,2 Hz), 1,15 e 1,24(cada 3H, cada s) , 80 1,54-2,54(14Η, m) , 4,31(1H, m) , 5,32-5,54(2H, m) , 6,36(1H, d, J=8,2 Hz), 6,93 e 7,48(cada 2H, cada d, J=8,6 Hz), 7,59 e 7,75 (cada 2H, cada d, J=8,4 Hz). IV (CHC13) : 3593, 3448, 3192, 3030, 3010, 2925, 2870, 1708, 1644, 1608, 1591, 1559, 1530, 1516, 1491/cm.
[a] D= +65,8° (MeOH, c=l,01, 25 °C) . N° 2a-80 c=l,01, 25 °C).
[a] D= +66,9o (MeOH, N° 2a-81 CDCI3 300 MHz 0,99(1H, d, J=10,5 Hz), 1,15 e 1,24 (cada 3H, cada s) , 1,54-2,48(14H, m), 3,86(3H, s), 4,29(1H, m) , 5,34-5,52 (2H, m), 6,20(1H, d, J=8,7 Hz), 6,99 e 7,55 (cada 2H, cada d, J=9, 0 Hz), 7,61 e 7,77 (cada 2H, cada d, J=8,7 Hz). IV (CHCI3) : 3450, 3009, 2925, 2870, 2838, 1740, 1708, 1650, 1608, 1557, 1528, 1512, 1491/cm.
[a] D= +66,2° (MeOH, c=l,01, 25 °C) . N° 2a-82 [a] D= +57,7° (MeOH, c=l, 02, 24 °C) . N° 2a-83 CDCI3 300 MHz 0,97(1H, d, J=10,2 Hz), 1,12 e 1,23 (cada 3H, cada s) , 1,54-2,48(14H, m) , 2,33(3H, s), 4,26(1H, m) , 5,32-5,52 (2H, m), 6,25(1H, d, J=8,7 Hz), 7,16 e 7,75 (cada 2H, cada d, J=8,7 Hz). 81 IV (CHC13) : 3452, 3030, 3022, 3012, 2925, 2870, 1754, 1709, 1654, 1604, 1585, 1522, 1493/cm.
[α] D= +57,4° (MeOH, c=l,01, 24 °C) . N° 2a-84 [a] D= +57,8° (MeOH, c=l,01, 24 °C) . N° 2a-85 CDC13 300 MHz 0, 95 (1H, d, J=10,2 Hz), 1,12 e 1,22 (cada 3H, cada s) , 1,54-2,48(14H, m) , 4,25(1H, m) , 5, 32-5, 52 (2H, m) , 6,28(1H, d, J=8,7 Hz), 6,87 e 7,57(cada 2H, cada d, J=9,0 Hz). IV (CHCI3) : 3590, 3450, 3166, 3019, 3012, 2925, 2871, 1708, 1637, 1608, 1583, 1531, 1498/cm.
[a] D= +56,0° (MeOH, c=l,01, 24 °C) . N° 2a-86 [a] D= +59,3° (MeOH, c=l,01, 22 °C) . N° 2a-87 CDCI3 300 MHz 0, 98 (1H, d, J=10,0 Hz), 1,13 e l,23(cada 3H, cada s) , 1,54-2,48(14H, m) , 3,85(3H, s), 4,25(1H, m) , 5, 32-5, 53(2H, m) , 6,19 (1H, d, J=8,8 Hz), 6,93 e 7,69 (cada 2H, cada d, J=9,0 Hz). IV (CHCI3) : 3450, 3030, 3017, 3012, 2925, 2870, 2840, 1740, 1708, 1647, 1606, 1575, 1525, 1496/cm.
[a] D= +58,2° (MeOH, c=0, 99, 22°C). 82 N° 2a-88 [α] D= +50,9° (MeOH, c=l, 02, 25 °C) . N° 2a-89 CDC13 300 MHz 3H, cada s) , , 7,0 3 (1H, d, ddd, J=1,8, 2870, 1708, 0,99 (1H, d, J=10,2 Hz), 1,18 e l,26(cada 1,56-2,48(14H, m) , 4,29(1H, m) , 5,36-5,54 (2H, m) J=8,7 Hz), 7,21 (1H, s), 7,43(2H, m) , 7,74(1H, 6,9 e 8,7 Hz), 8,22(1H, dd, J=l,8 e 8,1 Hz). IV (CHCI3) : 3443, 3087, 3023, 3014, 2925, 1685, 1658, 1630, 1517, 1466/cm.
[a] D= +57,1° (MeOH, c=l,01, 22 °C) .
p.f. 117,0-118,0 °C N° 2a-90 [a] D= +54,1° (MeOH, c=l,01, 22 °C) . N° 2a-91 CDCI3 300 MHz 3H, cada s) , , 6,49-6,53 dd, J=0,9 e 2870, 1739, 0,97(1H, d, J=10,2 Hz), 1,13 e l,23(cada 1,52-2,46(14H,m) , 4,24(lH,m), 5,34-5,52(2H,m) (2H, m) , 7, 11 (1H, dd, J=0,9 e 3,6 Hz), 7,44(1H, 1,8 Hz) . IV (CHCI3) : 3437, 3033, 3022, 3014, 2925, 1708, 1655, 1595, 1520, 1472/cm.
[a] D= +55,0° (MeOH, c=l, 00, 22 °C) . N° 2a-92 [a] D= +50,3° (MeOH, c=l, 00, 22 °C) . 83 N° 2a-93 CDCI3 300 ΜΗζ 0,95( 1Η, d, J=10,5 Hz), 1,12 e 1,23 (cada 3H, cada s), 1,52-2,46 (14H, m) , 4,25(1H, m) , 5, 34-5, 52 (2H, m) , 6,12(1H, d, J=8,7 Hz) 7,07 (1H, dd, J=3,9 e 5,1 Hz), 7,45-7,48(2H, m) . IV (CHCI3) : 3450, 3023, 3011, 2925, 2870, 1739, 1708, 1645, 1531, 1501, 1471/cm.
[a] D= +49,1° (MeOH, c=l, 02, 24 °C) . N° 2a-94 [a] D= +51,5° (MeOH, c=l, 00, 24 °C) . N° 2a-95 CDCI3 300 MHz 0, 96 (1H, d, J=10,5 Hz), 1,11 e l,23(cada 3H, cada s) , 1,52-2,46(14H, m) , 4,25(1H, m) , 5, 34-5, 56 (2H, m) , 6,14(1H, d, J=8,7 Hz), 7,34 (2H, d, J=2,0 Hz), 7,85(1H, t, J=2,0 Hz). IV (CHCI3) : 3452, 3114, 3030, 3013 2925, 2870, 1708, 1649, 1535, 1498, 1471/cm.
[a] D= +55,5° (MeOH, c=l, 00, 25 °C) . p.f. 87,0-88,0 °C N° 2a-96 CD3OD 300 MHz 0, 94 (1H, d, J=10,2 Hz), 1,13 e l,22(cada 3H, cada s) , 1,50-1,76 (3H, m), 1, 94-2,39(11H, m), 4,11(1H, m), 5, 39-5,49(2H, m), 7,43-7,51 (2H, m) , 8,05(1H, m) . IV (KBr): 3369, 3084, 2985, 2921, 2868, 1630, 1566, 1538, 1503/cm.
[a] D= +38,8° (MeOH, c=l,01, 22 °C) . 84 N° 2a-97 CD3OD 300 ΜΗζ 3H, cada s) , , 10(1H, m), 1629, 1545, 0, 93 (1Η, d, J=9, 9 Hz), 1,13 e l,22(cada 1,48-1,58 (3H, m), 1, 96-2,36(11H, m) , 4 5, 35-5,50(2H, m) , 7,42-7,51(2H, m), 8,06(1H, m) . IV (KBr): 3447, 3087, 2987, 2922, 2868, 1501/cm.
[a] D= +52,9° (MeOH, c=l,01, 24 °C) . N° 2a-98 [a] D= +53,2° (MeOH, c=l, 02, 23 °C) . N° 2a-99 CDCI3 300 MHz 3H, cada s) , , 6,18 (1H, d, 1738, 1709, 0,97(1H, d, J=10,2 Hz), 1,12 e l,22(cada 1,26-2,45(24H, m) , 4,25(2H, m) , 5,34-5,52 (2H, m) J=8,7 Hz), 6,91 e 7,66(cada 2H, cada d, J=9,0 Hz) IV (CHCI3) : 3455, 3029, 3019, 2939, 2862, 1645, 1605, 1523, 1494/cm.
[a] D= +51,4° (MeOH, c=l, 0 0, 23 °C) . N° 2a-l00 [a] D= +49,3° (MeOH, c=l, 00, 24 °C) . N° 2a-l01 [a] D= +51,3° (MeOH, c=l, 00, 24 °C) . N° 2a-l02 85 [α] D= +48,8° (MeOH, c=l,01, 23 °C) . N° 2a-103 CDC13 300 MHz 0,94(1H, d, J=10,2 Hz), 1,12 e 1,22 (cada 3H, cada s) , 1,52-2,46(14H, m), 2,48(3H, d, J=0,3 Hz), 4,20(1H, m) , 5,32-5,54 (2H, m) , 6,46(1H, s 1), 7,12(1H, d, J=9, 0 Hz). IV (CHCI3) : 3415, 3144, 3029, 3011, 2926, 2871, 1708, 1671, 1598, 1538, 14564/cm.
[a] D= +49,6° (MeOH, c=l,01, 23 °C) . N° 2a-104 [a] D= +77,0° (MeOH, c=l, 02, 23 °C) . N° 2a-105 CDCI3 300 MHz 93(1H, d, J=9,9 Hz), 1,09 e 1,21(cada 3H, cada s) , 1,51-2,44(14H, m) , 3,90(6H, s), 4,20(1H, m), 5,38-5,50 (2H, m) , 5,87(1H, d, J=9,0 Hz), 6,25 e 7,54 (cada 1H, cada d, J=15, 6 Hz), 6,84 (1H, d, J=8,1 Hz), 7,03(1H, d, J=l,8 Hz), 7,09 (1H, dd, J=1,8 e 8,1 Hz). IV (CHCI3) : 3439, 3028, 3012, 2937, 2871, 2841, 1739, 1708, 1661, 1620, 1600, 1513/cm.
[a] D= +77,3° (MeOH, c=l,01, 23 °C) . N° 2a-l06 [a] D= +67,0° (MeOH, c=l, 00, 25 °C) . N° 2a-107 86 [α] D= +66,6° (MeOH, c=l,01, 24 °C) .
p.f. 168,0-170,0 °C N° 2a-l08 [a] D= +61,8(MeOH, c=l, 00, 22 °C) . N° 2a-l09 CDC13 300 MHz 0,96(1H, d, J=10,2 Hz), 1,10 e 1,22 (cada 3H, cada s) , 1,51-2,45 (14H, m), 4,25(1H, m), 5,33-5,49(2H, m), 6,21(1H, d, J=8,7 Hz), 7,25 e 7,60(cada 2H, cada d, J=8,7 Hz), 7,33-7,41 (5H, s) . IV (CHCI3) : 3453, 3062, 3028, 3014, 2925, 2870, 1739, 1708, 1651, 1594, 1557, 1515, 1481/cm.
[a] D= +61,0° (MeOH, c=l,01, 22 °C) . N° 2a-l10 CD3OD 300 MHz 0,94(1H, d, J=9, 9 Hz), 1,13 e 1,22 (cada 3H, cada s) , 1,54-2,37 (14H, m), 4,12(1H, m), 5,38-5,49 (2H, m), 7,25 e 7,68(cada 2H, cada d, J=8,7 Hz), 7,41(5H, s). IV (KBr): 3435, 3058, 2986, 2920, 2866, 1635, 1595, 1562, 1521, 1482, 1439, 1411/cm.
[a] D= +47,3° (MeOH, c=l,01, 23 °C) . N° 2a-l11 [a] D= +65,6° (MeOH, c=l,01, 24 °C) . 87 N° 2a-l12 CDC13 300 ΜΗζ 3H, cada s) , , 6,22 (1H, d, 2841, 1739, 0,97(1Η, d, J=10,2 Ηζ), 1,12 e l,23(cada 1,51-2,46(14Η, m) , 4,27(1Η, m) , 5,35-5,50(2Η, m) J=8,4 Hz), 7,40 e 7,66(cada 2H, cada d, J=9,0 Hz), IV (CHCI3) : 3439, 3028, 3012, 2937, 2871, 1708, 1661, 1620, 1600, 1513/cm.
[a] D= +65,6° (MeOH, c=l,01, 22 °C) . N° 2a-113 [a] D= +59,6° (MeOH, c=l, 00, 24 °C) . N° 2a-114 CDCI3 300 MHz 3H, cada s) , , 6,28 (1H, d, 2841, 1739, 0,98 (1H, d, J=10,2 Hz), 1,12 e l,24(cada 1,52-2,46 (14H, m) , 4,29(1H, m) , 5,35-5,51(2H, m) J=8,4 Hz), 7,70 e 7,83(cada 2H, cada d, J=8,4 Hz), IV (CHCI3) : 3439, 3028, 3012, 2937, 2871, 1708, 1661, 1620, 1600, 1513/cm.
[a] D= +60,6° (MeOH, c=l,01, 22 °C) . N° 2a-115 [a] D= +59,7° (MeOH, c=0, 99, 24 °C) . N° 2a-l16 CDCI3 300 MHz 3H, cada s) , 5,51 (2H, m) , 0,97 (1H, d, J=10,2 Hz), 1,12 e l,23(cada 1,52-2,46 (14H, m) , 2,39(3H, s), 4,27(1H, m), 5,33 88 6,24(1H, d, J=9,0 Hz), 7,23 e 7,62(cada 2H, cada d, J=8,4 Hz) . IV (CHCI3) : 3439, 3028, 3012, 2937, 2871, 2841, 1739, 1708, 1661, 1620, 1600, 1513/cm. [a] D= +59,7° (MeOH, c=0, 99, 24 °C) . N° 2a-117 [α] D= +56,7° (MeOH, c=l,00, 23 °C) . N° 2a-118 CDCI3 300 MHz 0, 96 (1H, d, J=10,2 Hz), 1,11 e 1,23 (cada 3H, cada s) , 1,53-2,44 (14H, m) , 4,23(1H, m) , 5, 34-5, 51 (2H, m) , 6,02(2H, s) , 6,13 (1H, d, J=8,7 Hz), 6,83(1H, dd, J=l,2 e 7,8 Hz), 7,22-7,25(2H, m). IV (CHCI3) : 3453, 3031, 3020, 3012, 2924, 2870, 1740, 1708, 1650, 1619, 1605, 1519, 1504, 1480/cm.
[a] D= +57,2° (MeOH, c=l, 02, 23 °C) . N° 2a-l19 CDCI3 300 MHz 0, 96 (1H, d, J=10,5 Hz), 1,07 e 1,23 (cada 3H, cada s) , 1,51-2,44(14H, m) , 2,32(3H, s), 4,26(1H, m) , 5, 37-5, 52(2H, m), 6,40 (1H, d, J=9, 0 Hz), 7,09(1H, m) , 7,30(1H, m) , 7,46(1H, m) , 7,66 (1H, m) . IV (CHCI3) : 3443, 3028, 3012, 2925, 2870, 1766, 1747, 1709, 1657, 1607, 1516, 1479/cm.
[a] D= +53,2° (MeOH, c=0,99, 21 °C) . N° 2a-120 89 CDC13 300 MHz 3H, cada s) , , 6,4 2(1H, d, ,4 Hz), 7,27 2924, 2870, 0,98 (1H, d, J=10,2 Hz), 1,14 e l,24(cada 1,53-2,44(14H, m) , 4,30(1H, m) , 5,35-5,52 (2H, m) , J=8,7 Hz), 6, 85 (1H, m) , 6,99(1H, dd, J=l,2 e 8 (1H, m) , 7,3 9 (1H, m) . IV (CHCI3) : 3463, 3033, 3021, 3014, 2992, 1708, 1643, 1597, 1523, 1488/cm. [a] D= +46,3° (MeOH, c=l,01, 21 °C). N° 2a-121 CDC13 300 MHz 3H, cada s) , -5,50 (2H, m) , 9, 7,7 e 8,4 8,32(1 H, d, 2924, 2870, 0,98(1H, d, J=10,2 Hz), 1,14 e l,23(cada 1,47-2,47 (14H, m) , 3,95(3H, s), 4,31(1H, m) , 5,32 6, 98 (1H, dd, J=0, 9 e 8,4 Hz), 7,09(1H, ddd, J=0,
Hz) , 7,45 (1H, m) , 8,19(1H, dd, J=2,1 e 8 ,1 Hz), O II >~D Hz) . IV (CHCI3) : 3400, 3078, 3028, 3020 , 3007, 2842, 1736, 1708, 1640, 1600, 1536, 1483, 1470/cm, [a] D= +38,1° (MeOH, O O OO C\1 C\1 0 \—1 11 0 N° 2a-122 [a] D= +42,3° (MeOH, c=0, 99, 23 °C) . N° 2a-123 [a] D= +38,7° (MeOH, c=l,00, 21 °C) . N° 2a-124
[a] D= +45,0° (MeOH, c=l,01, 21 °C) . p.f. 119,0-120,0 °C 90 N° 2a-125 [α] D= +49,8° (MeOH, c=l,01, 22 °C) . N° 2a-126 CDC13 300 MHz 0,97(1H, d, J=10,2 Hz), 1,11 e l,23(cada 3H, cada s) , 1,52-2,47(14H, m) , 4,26(1H, m) , 5,34-5,50(2H, m) , 6,22(1H, d, J=8,7 Hz), 7,55-7,61 (4H, m) . IV (CHCI3) : 3400, 3078, 3028, 3020, 3007, 2924, 2870, 2842, 1736, 1708, 1640, 1600, 1536, 1483, 1470/cm.
[a] D= +63,0(MeOH, c=l,01, 23°C.). 2a-127 CDCI3 300 MHz 0, 91 (1H, d, J=10,2 Hz), 1,10 e 1,20 (cada 3H, cada s) , 1,50-2,42(14H, m) , 4,23(1H, m) , 5, 31-5,51(2H, m) , 6,45(1H, d, J=8,4 Hz), 7,01(1H, t, J=7,4 Hz), 7,22(2H, m), 7,33-7,40 (4H, m) , 7,53(2H, d, J=9, 0 Hz), 8,30 e 8,48(cada 1H, cada s) IV (CHCI3) : 3452, 3028, 3022, 3015, 2925, 2870, 1708, 1654, 1590, 1514, 1478/cm.
[a] D= +59,5° (MeOH, c=l,01, 23 °C) . N° 2a-128 de-DMSO 300 MHz 0,84(1H, d, J=9, 9 Hz), 1,06 e 1,19 (cada 3H, cada s) , 1,37-2,37(14H, m) , 3,79(1H, m) , 5, 35-5,51(2H, m) , 6,08(1H, d, J=8,7 Hz), 6, 85-6, 90 (1H, m) , 7, 18-7,23 (2H, m) , 7,35-7,38 (2H, m) , 8,42 (1H, s), 12,00(1H, s) . IV (Nujol): 3395, 3345, 2925, 2866, 2623, 2506, 1697, 91 1658, 1638, 1597, 1557/cm.
[α] D= +26,0° (MeOH, c=l,01, 23 °C) . p.f. 164,0-166,0 °C N° 2a-129 CDC13 300 MHz 3H, cada s) , , 6,4 2 (1H, d, 8 e 8,6 Hz), 2870, 1708, 1,01 (1H, d, J=10,0 Hz), 1,17 e l,25(cada 1.54- 2,52(14H, m) , 4,34(1H, m) , 5,36-5,57(2H, m) J=8,6 Hz), 7,51-7,60 (2H, m) , 7,77(1H, dd, J=l, 7,85-7,96(3H, m), 8,24(1H, s 1). IV (CHCI3) : 3451, 3060, 3028, 3010, 2925, 1652, 1629, 1600, 1517, 1502/cm.
[a] D= +68,6° (MeOH, c=l, 00, 22 °C) . N° 2a-130 CDCI3 300 MHz 3H, cada s) , , 6,14(1H, d, 8,27 (1H, dd, 2664, 1708, 1,02(1H, d, J=10,2 Hz), 1,04 e 1,26(cada 1.54- 2,52(14H, m) , 4,41(1H, m) , 5,41-5,58(2H, m) J=9, 0 Hz), 7,43-7,59(4H, m) , 7, 85-7, 92 (2H, m) , J=l, 8 e 7,2 Hz) . IV (CHCI3) : 3436, 3032, 3010, 2924, 2870, 1652, 1512, 1498/cm.
[a]D= +93,9° (MeOH, c=l,00, 22 °C) p.f. 94,0-96,0 °C N° 2a-131 [a] D= +50,2° (MeOH, c=0,95, 21 °C) . N° 2a-132 92 [α] D= +10,9° (MeOH, c=0,92, 21 °C) . N° 2a-133 [a] D= +60,4° (MeOH, c=l,0 0, 21 °C) . N° 2a-134 [a] D= +38,5° (MeOH, c=l,01, 23 °C) . N° 2a-135
[a] D= +52,5° (MeOH, c=l,01, 23 °C) . p.f. 180,0-182,0 °C N° 2a-136
[a] D= +35,3° (MeOH, c=l, 02, 23 °C) . p.f. 79,0-80,0 °C
[0941] N° 2a-137 CDC13 300 MHz 9 0,97(1H, d, J=10,2 Hz), 1,11 e 1,22 (cada 3H, cada s) 1,4 3 (3H, t, J=6,9 Hz), 1,52-2,44 (14H, m) , 4,03(2H, q, J=6, Hz), 4,26(1H, m), 5,33-5,50 (2H, m), 6,19(1H, d, J=8,7 Hz) 6, 88 — 7, 00(6H, m) , 7, 65-7, 68 (2H, m) . IV (CHCI3): 3455, 3031, 3024, 3014, 2988, 2925, 2870 1741, 1708, 1649, 1602, 1521, 1504, 1490/cm.
[a]D= +52,0° (MeOH, c=l,01, 23 °C) . 93 N° 2a-138 CDCI3 300 ΜΗζ 0,97( 1Η, d, J=10,2 Hz), 1,11 e l,22(cada 3H, cada s) , 1,35 ( 6H, d, J=6,0 Hz), 1,53-2,46(14H, m), 4,25(1H, m) , 4,51 (1H, m) , 5,33-5,50 (2H, m) , 6,12(1H, d, J=9,0 Hz), 6, 87-6, 99 (6H, m), 7, 65-7, 68 (2H, m) . IV (CHCI3) : 3454, 3031, 3014, 2980, 2925, 2870, 1741, 1708, 1649, 1602, 1522, 1490/cm.
[a] D= +50,0° (MeOH, c=l, 05, 22 °C) . N° 2a-139 CDCI3 300 MHz 1,0 0 (1H, d, J=10,2 Hz), 1,16 e l,24(cada 3H, cada s), 1,59-2,52 (14H, m) , 4,31(1H, m) , 5, 40-5, 53 (2H, m) , 6,36(1H, d, J=8,7 Hz), 6,7 0 (1H, d, J=l,5 Hz), 7,12(1H, m) , 7,30(1H, m) , 7,47 (1H, dd, J=0,6 e 8,1 Hz), 7,61(1H, d, J=8,4 Hz). IV (CHCI3) : 3449, 8243, 3029, 3022, 3013, 2925, 2871, 1707, 1631, 1542, 1505/cm.
[a] D= +63,4° (MeOH, c=l, 00, 23 °C) .
p.f. 178,0-179,0 °C N° 2a-140 CDCI3 300 MHz 0, 97 (1H, d, J=10,2 Hz), 1,18 e l,23(cada 3H, cada s) , 1,57-2,50(14H, m) , 4,35(1H, m) , 5,32-5,56(2H, m) , 6,42(1H, d, J=8,7 Hz), 6,70 (1H, d, J=l,5 Hz), 7,21-7,24(2H m) , 7,46(1H, m) , 7,7 6 (1H, m) , 7,86(1H, d, J=3, 0 Hz), 10,20(1H, s) . IV (CHCI3) : 3465, 3010, 2924, 1739, 1604, 1546, 1504/cm.
[a] D= +39,4° (MeOH, c=l,01, 22 °C) .
p.f. 167,0-168,0 °C 94 N° 2a-141 CDC13 300 ΜΗζ 0,99(1Η, d, J=10,2 Hz), 1,14 e 1,24 (cada 3H, cada s) , 1,55-2,44(14H, m) , 3,84(3H, s), 4,27(1H, m) , 5,34-5,52(2H, m), 6,28(1H, d, J=9,0 Hz), 6,91 e 7,47(cada 2H, cada d, J=9, 0 Hz), 6,98 e 7,14(cada 1H, cada d, J=16,5 Hz), 7,54 e 7,70(cada 2H, cada d, J=8,7 Hz) .
IV (CHCI3) : 3453, 1708 , 1649, 1602, 1510, [a] D= +73,4° (MeOH p.f. 155,0-157,0 0 N° 2a-142 CDCI3 300 MHz 0,97(1H, d, J=10, 1,52 -2,45(14H, m) , 3, li 6,24 (1H, d, J=9,0 Hz) , Hz) , 6,77 e 7,16(cada 2H, cada d, J=8,1 Hz) . IV (CHCI3) : 3453, 1708 , 1649, 1606, 1510, [a] D= +60,7° (MeOH N° 2a-143 [a]D= +57,3° (MeOH N° 2a-144 [a] D= +12,2° (MeOH
p.f. 114,0-116,0 °C 95 N° 2a-145 CDC13 300 ΜΗζ 0, 95 (1Η, d, J=10,2 Ηζ), 1,10 e l,21(cada 3Η, cada s) , 1,52-2,44(14H, m) , 4,25(1H, m) , 5,33-5,49 (2H, m) , 6,37(1H, d, J=8,7 Hz), 7,45-7,47 (3H, m) , 7, 62-7, 66(2H m) , 7,69 e 7,80(cada 2H, cada d, J=7,5 Hz, ). IV (CHCI3) : 3449, 3058, 3027, 3012, 2925, 2870, 1708, 1655, 1513, 1481, 1043/cm.
[a] D= +61,0° (MeOH, c=l,01, 23 °C) . N° 2a-146 CDCI3 300 MHz 0, 95 (1H, d, J=10,5 Hz), 1,09 e l,21(cada 3H, cada s) , 1,50-2,41 (14H, m) , 4,25(1H, m) , 5,33-5,4 9 (2H, m) , 6,33(1H, d, J=8,4 Hz), 7,49-7, 61(3H, m) , 7,91-7,92(2H, m) , 7,82 e 7,97(cada 2H, cada d, J=8,7 Hz,). IV (CHCI3): 3447, 3029, 3023, 3015, 2925, 2870, 1708, 1660, 1514, 1484, 1321, 1161/cm.
[a] D= +62,0° (MeOH, c=l, 00, 22 °C) . N° 2a-147 CDCI3 300 MHz; 0,97(1H, d, J=10,2 Hz), 1,12 e 1,23 (cada 3H, cada s) , 1,52-2,46 (14H, m), 2,51(3H, s), 4,26(1H, m), 5,34-5,51(2H, m), 6,23(1H, d, J=8,4 Hz), 7,26 e 7,64(cada 2H, cada d, J=8,4 Hz) . IV (CHCI3) : 3453, 3027, 3015, 2925, 2870, 2665, 1708, 1648, 1596, 1516, 1484/cm.
[a]D= +67,7° (MeOH, c=0,82, 226 °C) . 96 N° 2a-148 [α] D= +72,5° (MeOH, c=l,01, 25 °C) . N° 2a-149 [a] D= +67,8° (MeOH, c=0, 98, 25 °C) . N° 2a-150 CDC13 300 MHz 3H, cada s) , , 6,48 (1H, d, 2925, 2871, 0,94 (1H, d, J=10,2 Hz), 1,10 e l,23(cada 1,52-2,50(14H, m) , 4,22(1H, m) , 5,36-5,55 (2H, m) , J=8,4 Hz), 8,35 (1H, s), 8,90(1H, s). IV (CHCI3) : 3443, 3374, 3091, 3024, 3012, 1709, 1652, 1525, 1494/cm.
[a] D= +58,1° (MeOH, c=l,01, 23 °C) . p.f. 120,0-122,0 °C N° 2a-151 [a] D= +40,6° (MeOH, c=l,01, 23 °C) . N° 2a-152 CDCI3 300 MHz 3H, cada s) , -5,51 (2H, m) , 2925, 2870, 0,96(1H, d, J=10,5 Hz), 1,10 e 1,24(cada 1,50-2,50(14H, m) , 2,71(3H, s), 4,26(1H, m) , 5,37 6,02(1H, d, J=9,0 Hz), 8,73(1H, s). IV (CHCI3) : 3463, 3435, 3087, 3025, 3014, 1708, 1649, 1523, 1503/cm.
[a] D= +54,1° (MeOH, c=l, 02, 22 °C) . 97 N° 2a-153 CDC13 300 ΜΗζ 0,95(1Η, d, J=9, 9 Hz) , 1,11 e l,23(cada 3H, cada s) , 1,50-2,50(14H, m), 2,50(3H, s), 4,26(1H, m) , 5,36-5,51(2H, m), 6,01(1H, d, J=8,4 Hz), 6,88(1H, d, J=5,l Hz), 7,26(1H, d, J=5,1 Hz) . IV (CHCI3) : 3469, 3431, 3025, 3013, 2925, 2871, 2664, 1708, 1639, 1544, 1505/cm.
[a] D= +35,8° (MeOH, c=l, 03, 22 °C) . N° 2a-154 CDCI3 300 MHz 0, 95 (1H, d, J=9, 9 Hz), 1,10 e l,22(cada 3H, cada s) , 1.52- 2,46(14H, m), 2,51(3H, d, J=l,2 Hz), 4,26(1H, m) , 5,34-5,50(2H, m), 6,00(1H, d, J=8,4 Hz), 6,73(1H, dd, J=5,l e 3,6 Hz), 7,29 (1H, d, J=3, 6 Hz). IV (CHCI3): 3450, 3431, 3026, 3011, 2925, 2869, 1739, 1708, 1639, 1547, 1508/cm.
[a] D= +50,5° (MeOH, c=l,01, 22 °C) . N° 2a-155 CDCI3 300 MHz 0,99(1H, d, J=10,2 Hz), 1,19 e 1,25 (cada 3H, cada s) , 1.53- 2,48 (14H, m) , 4,31(1H, m) , 5, 36-5, 51 (2H, m) , 6,79(1H, d, J=9, 3 Hz), 7,29 (1H, m) , 7,41(1H, m) , 7,48(1H, s) , 7,51(1H, m) , 7,66(1H, d, J=8,1 Hz). IV (CHCI3) : 3436, 3029, 3024, 3015, 2925, 2871, 2670, 1708, 1659, 1598, 1510/cm.
[a] D= +69,1° (MeOH, c=l,01, 22 °C) . 98 N° 2a-156 CDC13:CD30D=10 :1 300 MHz 0,99(1H, d, J=9, 9 Hz), 1,11 e 1,21 (cada 3H, cada s) , 1,56-2,58(14H, m) , 4,22(1H, m) , 5,35-5,59 (2H, m) , 6,83(1H, d, J=8,4 Hz), 7,4 8 (1H, d, J=8,4 Hz), 7,61(1H, dd, J=l,5 e 8,4 Hz), 8,0 9 (1H, d, J=1,5 Hz), 8,12(1H, s). IV (KBr): 3422, 3115, 2985, 2922, 2869, 2609, 1708, 1636, 1578, 1529, 1470/cm.
[a] D= +62,8° (MeOH, c=l,01, 22 °C) . N° 2a-157 [a] D= +40,0° (MeOH, c=0, 95, 22 °C) . N° 2a-158 CDCI3 300 MHz 1,0 0 (1H, d, J=10,5 Hz), 1,17 e 1,24 (cada 3H, cada s), 1.54- 2,50(14H, m) , 4,34(1H, m) , 5, 36-5, 52(2H, m) , 7,80(1H, d, J=9, 0 Hz) , 9,30 (1H, s) . IV (CHCI3) : 3410, 3122, 3030, 3012, 2925, 2871, 2668, 1709, 1667, 1538, 1466/cm.
[a] D= +44,9° (MeOH, c=0, 99, 220 °C) . N° 2a-159 CDCI3 300 MHz 0, 97 (1H, d, J=10,2 Hz), 1,13 e 1,22 (cada 3H, cada s) , 1.55- 2,43(14H, m), 3,03(6H, s), 4,23(1H, m) , 5,32-5,51(2H, m), 6,16(1H, d, J=8,7 Hz), 6,87 e 7,63(cada 2H, cada d, J=8,7 Hz). IV (CHCI3) : 3457, 3028, 3006, 2924, 2870, 2654, 1739, 1709, 1637, 1608, 1608, 1534, 1501/cm. 99 [ α] D= +64,8° (MeOH, c=l,01, 22 °C) . N° 2a-l60 dg-DMSO 300 MHz 0,83(1H, d, J=9, 9 Hz), 1,02 e 1,19 (cada 3H, cada s) , 1,38-1,61 (3H, m), 1, 90-2,32(11H, m), 3,90(1H, m), 5, 41-5,44 (2H, m) , 7,32(1H, dd, J=0,9 e 7,2 Hz), 7,45-7,60 (2H, m) , 7,77 (1H, dd, J=0,9 e 7,8 Hz), 8,03(1H, d, J=6, 9 Hz), 12,40 (1H, s) . IV (Nujol): 3315, 2924, 2856, 2656, 2535, 1737, 1703, 1637, 1598, 1581, 1541/cm.
[a] D= +78,5° (MeOH, c=l,01, 24 °C) . p.f. 161,0-162,0 °C N° 2a-l61 [a] D= +65,3° (MeOH, c=l, 00, 22 °C) . N° 2a-l62 CDC13 300 MHz 0,99(1H, d, J=10,2 Hz), 1,13 e 1,25 (cada 3H, cada s) , 1,53-2,45(14H, m) , 4,30(1H, m) , 5,36-5,51 (2H, m) , 6,32(1H, d, J=8,4 Hz), 7,88 e 8,28(cada 2H, cada d, J=9,0 Hz). IV (CHCI3) : 3448, 3029, 3016, 2925, 2870, 1708, 1664, 1602, 1527, 1484, 1347/cm.
[a] D= +72,7° (MeOH, c=l, 02, 22 °C) . N° 2a-l63 CDCI3 300 MHz 0,96 (1H, d, J=10,2 Hz), 1,11 e 1,23(cada 3H, cada s), 100 1,55-2,51(14Η, m) , 4,26(1H, m) , 5, 36-5, 57(2H, m) , 6,68(1H, d J=7,8 Hz), 7,41 (1H, dd, J=4,8 e 8,1Hz), 8,20(1H, d, J=8,l Hz) 8,6 6 (1H, d, J=4,8 Hz), 9,00(1H, s) . 2534, 1709, 3H, cada s) , 6, 63(1H, d, 2870, 2538, 3H, cada s) , -5,50 (2H, m) , d, J=8,4 Hz), 2806, 1739, IV (CHC13) : 3448, 3026, 3013, 2925, 2870, 1658, 1590, 1515, 1471/cm.
[a] D= +71,3° (MeOH, c=l,01, 22 °C) . N° 2a-l64 [a] D= +40,8° (MeOH, c=0, 98, 22 °C) . N° 2a-l65 CDCI3 300 MHz 0,96(1H, d, J=10,5 Hz), 1,11 e 1,24(cada 1,55-2,52(14H, m) , 4,24(1H, m) , 5, 37-5, 57(2H, m) , J=7,8 Hz), 7,59 e 8,63(cada 2H, cada d, J=6,0 Hz). IV (CHCI3) : 3447, 3346, 3028, 3016, 2925, 1941, 1708, 1662, 1556, 1516/cm.
[a] D= +75,4° (MeOH, c=l,01, 22 °C) . N° 2a-l66 CDCI3 300 MHz 0,97(1H, d, J=10,2 Hz), 1,11 e 1,22(cada 1,51-2,44 (14H, m) , 2,95(6H, s) , 4,25(1H, m) , 5,33 6,19(1H, d, J=8,7 Hz), 6,77 e 6,97(cada 2H, cada 6,94 e 7,65 (cada 2H, cada d, J=9,0 Hz). IV (CHCI3) : 3453, 3024, 3016, 2924, 2871, 1708, 1647, 1612, 1604, 1515, 1490/cm.
[a] D= +53,1° (MeOH, c=l, 02, 23 °C) . p.f. 104,0-105,5 °C 101 N° 2a-l67 CDCI3 300 ΜΗζ 1,01(1Η, d, J=9, 9 Hz), 1,19 e l,26(cada 3H, cada s) , 1.56- 2,53(14H, m) , 4,37(1H, m) , 5,35-5,55(2H, m) , 6,47(1H, d, J=8,4Hz), 7, 61-7,71(2H, m), 7,79(2H, s), 7,89-7, 97 (2H, m), 8,27(1H, d, J=2,1 Hz), 8,66-8,73(2H, m). IV (CHCI3) : 3450, 3024, 3014, 2925, 2870, 2667, 1707, 1650, 1531, 1509/cm.
[a] D= +70,5° (MeOH, c=l, 00, 22 °C) . N° 2a-l68 CDCI3 300 MHz 1,02 (1H, d, J=10,2 Hz), 1,20 e l,26(cada 3H, cada s), 1.56- 2,50(14H, m) , 4,38(1H, m) , 5,36-5,56(2H, m) , 6,51(1H, d, J=8,4 Hz), 7,61-7,93 (7H, m), 8,74(1H, d, J=8,4 Hz), 9,15 (1H, s) . IV (CHCI3) : 3517, 3451, 3060, 3028, 3011, 2925, 2870, 2664, 1709, 1651, 1519, 1498/cm.
[a] D= +54,4° (MeOH, c=l, 00, 23 °C) . N° 2a-169 CDCI3 300 MHz 0, 96 (1H, d, J=10,5 Hz), 1,09 e l,21(cada 3H, cada s) , 1,50-2,44(14H, m), 3,85(3H, s), 4,24(1H, m) , 5,32-5,48(2H, m), 6,19 (1H, d, J=8,4 Hz), 6,94 e 7,45(cada 2H, cada d, J=9,0 Hz), 7,11 e 7,45(cada 2H, cada d, J=8,7 Hz). IV (CHCI3) : 3516, 3453, 3029, 3009, 2925, 2870, 2840, 2665, 1708, 1650, 1593, 1515, 1493, 1482/cm.
[a] D= +57,8° (MeOH, c=l, 00, 23 °C) . 102 N° 2a-170 CDC13 300 ΜΗζ 0,98 (1Η, d, J=10,2 Hz), 1,15 e 1,24 (cada 3H, cada s), 1.52- 2,50(14H, m) , 4,28(1H, m) , 5, 33-5, 54 (2H, m) , 6,25(1H, d, J=8,2 Hz), 7,38-7,44(2H, m) , 7,74(1H, s), 7,81-7,86(2H, m) . IV (CHCI3) : 3517, 3448, 3427, 3024, 3013, 2925, 2870, 2669, 1708, 1650, 1562, 1535, 1500/cm.
[a] D= +61,6° (MeOH, c=l, 00, 23 °C) . N° 2a-171 CDCI3 300 MHz 0,96(1H, d, J=10,2 Hz, 1,11 e 1,22 (cada 3H, cada s) , 1.52- 2,42(14H, m) , 2,48(3H, s), 4,21(1H, m) , 6,31-5,52(2H, m), 6,06(1H, d, J=8,2 Hz), 6,97 e 7,59(cada 1H, cada d, J=l,2 Hz). IV (CHCI3) : 3452, 3113, 3028, 3007, 2925, 2870, 2669, 1708, 1645, 1554, 1509/cm.
[a] D= +52,4° (MeOH, c=l, 00, 23 °C) . N° 2a-172 CDCI3 300 MHz 0,96(1H, d, J=10,2 Hz), 1,09 e 1,28 (cada 3H, cada s) , 1,50-2,40(14H, m) , 2,69(3H, s), 4,24(1H, m) , 5,35-5,51(2H, m), 5,96 (1H, d, J=8,7 Hz), 7,03 e 7,07(cada 1H, cada d, J=5,4 Hz). IV (CHCI3) : 3451, 3031, 3013, 2925, 2870, 2666, 1708, 1647, 1542, 1497/cm.
[a] D= +51,2° (MeOH, c=l, 0 0, 23 °C) . N° 2a-173 CDCI3 300 MHz 103 0, 95 (1Η, d, J=10,2 Hz), 1,10 e 1,23 (cada 3H, cada s) , 1.50- 2,45 (14H, m) , 4,22(1H, m) , 5,35-5,49 (2H, m) , 6,05(1H, d, J=8,4 Hz), 7,26 e 7,75(cada 1H, cada d, J=l,5 Hz). IV (CHC13) : 3451, 3011, 3029, 3011, 2925, 2870, 1708, 1652, 1538, 1500/cm.
[a] D= +50,6° (MeOH, c=l,01, 23 °C) . N° 2a-174 CDCI3 300 MHz 0, 96 (1H, d, J=10,2 Hz), 1,13 e 1,23 (cada 3H, cada s) , 1,52-2,50 (14H, m) , 4,29(1H, m) , 5, 35-5, 51 (2H, m) , 7,02(1H, d, J=8,4 Hz), 7,32 e 8,16(cada 1H, cada d, J=3,9 Hz). IV (CHCI3) : 3417, 3115, 3023, 3014, 2925, 2870, 1708, 1645, 1530/cm.
[a] D= +48,8° (MeOH, c=l, 02, 23 °C) . N° 2a-175 CDCI3 300 MHz 0, 97 (1H, d, J=10,2 Hz), 1,14 e 1,23 (cada 3H, cada s) , 1.50- 2,52(14H, m), 2,52(3H, s), 4,29(1H, m) , 5,34-5,51(2H, m), 7,78(1H, d, J=9, 0 Hz), 7,24 e 7,52(cada 1H, cada d, J=5,4 Hz). IV (CHCls) : 3329, 3093, 3023, 3015, 2924, 2871, 1708, 1640, 1526/cm.
[a] D= +45,0° (MeOH, c=l,01, 23 °C) . N° 2a-176 CDCI3 300 MHz 0,95(1H, d, J=10,5 Hz) , 1,09 e 1,23 (cada 3H, cada s) 1,52-2,46 (14H, m) , 2,40(3H, d, J=0, 9 Hz), 4,24(1H, m) 5, 35-5, 51(2H, m) , 6,05 (1H, d, 00 II •d 7 Hz) , 6, 95(1H, m) , 7, 57 104 (1Η, d, J=3,3 Hz) . IV (CHCI3) : 3517, 3444, 3103, 3024, 3013, 1739, 1708, 1649, 1636, 1507/cm. [a] D= +54,8 0 (MeOH, O 0 00 c\] 1 -1 0 \—1 11 υ p.f. 97,0-99, O O O 2926, 2870, N° 2a-177 CDC13 300 MHz 3H, cada s) , -5,50 (2H, m) , 8,10 (1H, d, 2925, 2871, 3H, cada s) , - 6,09(1H, d, 3011, 2925, 3H, cada s) , 6,73(1H, d, 0,97(1H, d, J=10,2 Hz), 1,19 e 1,23(cada 1,52-2,45(14H, m) , 3,93(3H, s) , 4,27(1H, m) , 5,34 6,35(1H, d, J=3,3 Hz), 7,80(1H, d, J=8,7 Hz), J=3,3 Hz) . IV (CHCla): 3395, 3121, 3031, 3019, 3012, 1739, 1709, 1640, 1557, 1533/cm.
[a] D= +22,8° (MeOH, c=l,01, 23 °C) . p.f. 109,0-112,0 °C N° 2a-178 CDCI3 300 MHz 0,96(1H, d, J=10,5 Hz), 1,10 e 1,23(cada 1,51-2,45(14H, m) , 4,24(1H, m) , 5,35-5,50(2H, m) , J=8,4 Hz), 7,17-7,31 (6H, m), 7,95(1H, d, J=l,5 Hz) IV (CHC13) : 3510, 3451, 3062, 3031 , 3022, 2870, 2662, 1708, 1651, 1582, 1535, 1497, 1477/cm, [a] D= +47,9o (MeOH, c=l,01, 25 °C). N° 2a-179 CDCI3 300 MHz 0,96(1H, d, J=10,2 Hz), 1,14 e l,24(cada 1,52-2,48(14H, m) , 4,30(1H, m) , 5,36-5,52(2H, m) , 105 J=9,0 Hz), 6,26 e 7,37(cada 1H, cada d, J=6,0 Hz). IV (CHC13) : 3509, 3429, 3115, 3094, 3025, 3014, 2925, 2871, 2666, 1708, 1649, 1529, 1510/cm.
[a]D= +51,0° (MeOH, c=l, 02, 25 °C) . N° 2a-l80 CDCI3 300 MHz 0,95(1H, d, J=10,2 Hz), 1,14 e 1,24 (cada 3H, cada s) , 1.52- 2,46(14H, m), 3,89(3H, s), 4,21(1H, m) , 5, 35-5, 50(2H, m), 6,05(1H, d, J=8,4 Hz), 6,46 e 7,04(cada 1H, cada d, J=l,8 Hz). IV (CHCI3) : 3516, 3450, 3114, 3031, 3010, 2925, 2871, 1708, 1648, 1546, 1511, 1477/cm.
[a] D= +49,1° (MeOH, c=l,01, 25 °C) . N° 2a-181 CDCI3 300 MHz 0, 97 (1H, d, J=10,2 Hz), 1,14 e 1,23 (cada 3H, cada s), 1.52- 2,48(14H, m) , 2,42(3H, s), 4,31(1H, m) , 5, 34-5, 52(2H, m), 8,07(1H, d, J=9,3 Hz), 7,27 e 8,17(cada 1H, cada d, J=3,3 Hz). IV (CHCI3): 3510, 3301, 3112, 3023, 3007, 2924, 2871, 2663, 1708, 1636, 1534/cm.
[a] D= +41,0° (MeOH, c=0, 96, 25 °C) . N° 2a-182 CDCI3 300 MHz 0, 9 6 (1H, d, J=10,2 Hz), 1,11 e l,23(cada 3H, cada s) , 1.53- 2,46(14H, m), 2,51(3H, s), 4,21(1H, m) , 5,35-5,51(2H, m), 6,05(1H, d, J=8,l Hz), 7,26 e 7,78(cada 1H, cada d, J=l,8 Hz). IV (CHCI3) : 3509, 3450, 3109, 3024, 3012, 2925, 2870, 2666, 1708, 1650, 1535, 1498, 1471/cm. 106 [α] D= +52,9° (MeOH, c=0, 95, 25 °C) . N° 2a-183 CDC13 300 MHz 0,96(1H, d, J=10,5 Hz), 1,12 e 1,22 (cada 3H, cada s) , 1,52-2,46(14H, m) , 4,25(1H, m) , 5,33-5,51 (2H, m) , 6,17(1H, d, J=8,7 Hz), 7,01-7,05 (3H, m) , 7,14 e 7,62(cada 2H, cada d, J=8,7 Hz), 7,27-7,34 (2H, m) . IV (CHCI3) : 3428, 3026, 3015, 2925, 2870, 2666, 1739, 1708, 1643, 1613, 1594, 1526, 1499/cm.
[a] D= +64,8° (MeOH, c=l, 02, 23 °C) . N° 2a-l84 CDCI3 300 MHz 1,01(1H, d, J=10,2 Hz), 1,18 e 1,26 (cada 3H, cada s) , 1.55- 2,50 (14H, m) , 4,35(1H, m) , 5,35-5, 55 (2H, m) , 6,42(1H, d, J=8,7 Hz), 7,46-7,52 (2H, m) , 7,73(1H, dd, J=l,8 e 8,4 Hz), 7, 83-7, 89 (2H, m), 8,21(1H, m), 8,59(1H, d, J=l,5 Hz). IV (CHCI3) : 3451, 3031, 3014, 2925, 2870, 2660, 1739, 170821650, 1604, 1513, 1463/cm.
[a] D= +58,3° (MeOH, c=l, 00, 23 °C) . N° 2a-185 CDCI3 300 MHz 1,00(1H, d, J=10,2 Hz), 1,18 e 1,25 (cada 3H, cada s) , 1.55- 2,50(14H, m) , 4,34(1H, m) , 5, 35-5, 54(2H, m) , 6,36(1H, d, J=8,7 Hz), 7,37 (1H, t, J=7,4 Hz), 7,50(1H, m) , 7,57-7,59(2H, m) , 7,7 9 (1H, dd, J=l,8 e 8,1 Hz), 7,99(1H, d, J=7,8 Hz), 8,39(1H, d, J=1,8 Hz) . IV (CHCI3) : 3451, 3030, 3020, 2870, 2665, 1708, 1652, 107 1632, 1603, 1586, 1514, 1469, 1448/cm.
[α] D= +59,4° (MeOH, c=l,01, 24 °C) . N° 2a-186 CDC13 300 MHz 1, 0 0 (1H, d, J=10,5 Hz), 1,17 e 1,25 (cada 3H, cada s) , 1,54-2,50(14H, m) , 4,33(1H, m) , 5,35-5,54(2H, m) , 6,37(1H, d, J=8,7 Hz), 7,37(1H, t, J=7,4 Hz), 7,51(1H, t, J=7,8 Hz) , 7,5 6 (1H, m) , 7,70(1H, dd, J=l,2 e 8,4 Hz), 7,97(3H, m) . IV (CHCI3) : 3451 1708, 1652, 1577, 1517 , 3030, 3014, , 1488, 1471/cm. 2924, 2870, 2671, 1739, [a] D= +72,2° (MeOH, c=l, 00, 24 °C) . N° 2a-187 CDCI3 300 MHz 1, 0 0 (1H, d, J=9, 8 Hz), 1,18 e 1,25 (cada 3H, cada s) , 1,54-2,53 (14H, m) , 4,07(3H, s), 4,37(1H, m) , 5, 30-5, 54(2H, m), 7,34(1H, m) , 7,47(1H, s), 7,47-7, 60 (2H, m) , 7,93(1H, d, J=7,8
Hz), 8,43(1H, s), 8,4 9(1H, d, J=9,0 Hz). IV (CHCI3): 3397, 3074, 3027, 3020, 3009, 2924, 1738, 1708, 1647, 1633, 1534, 1465, 1453/cm.
[a] D= +43,7° (MeOH, c=l,01, 25 °C) . N° 2a-l88 CDCI3 300 MHz 0, 97 (1H, d, J=10,2 Hz), 1,11 e l,23(cada 3H, cada s) , 1,53-2,50(14H, m) , 4,23(1H, m) , 5,37-5,50(2H, m) , 6,10(1H, d, J=9, 0 Hz), 6,20 (1H, m) , 6,51(1H, m) , 6,97(1H, m) , 10,81 (1H, s 1) . IV (CHCI3) : 3450, 3236, 3112, 3029, 3015, 2925, 2871, 108 2645, 1701, 1616, 1558, 1516/cm.
[α] D= +50,6° (MeOH, c=l,01, 24 °C) . N° 2a-189 CDCI3 300 MHz 0,94(1H, d, J=9, 9 Hz), 1,11 e 1,23 (cada 3H, cada s) , 1,50-2,46(14H, m) , 3,93(3H, s) , 4,18(1H, m) , 5, 35-5, 52(2H, m) , 6, 03 (1H, d, J=9, 3 Hz), 6, 0 9 (1H, m) , 6,48(1H, m) , 6,73(1H, m) . IV (CHCI3) : 3452, 3102, 3028, 3007, 2925, 2871, 2666, 1739, 1708, 1650, 1536, 1499, 1471/cm.
[a] D= +49,8° (MeOH, c=l,01, 23 °C) . p.f. 101,5-103,5 °C N° 2a-l90 CDCI3 300 MHz 0, 94 (1H, d, J=10,2 Hz), 1,11 e 1,21 (cada 3H, cada s) , 1.54- 2,47(14H, m) , 4,23(1H, m) , 5, 33-5, 52 (2H, m) , 6,06(1H, d, J=9, 0 Hz), 6,34 (1H, m) , 6,75(1H, m) , 6,36(1H, m) , 9,71(1H, s 1) . IV (CHCI3) : 3470, 3215, 3030, 3020, 3010, 2925, 2871, 2664, 1709, 1613, 1564, 1510/cm.
[a] D= +43,3° (MeOH, c=l,01, 24 °C) . N° 2a-l91 CDCI3 300 MHz 0,96(1H, d, J=10,2 Hz), 1,11 e 1,22 (cada 3H, cada s) , 1.55- 2,44(14H, m) , 3,66 (3H, s), 4,20(1H, m), 5,35-5,51(2H, m), 5, 93 (1H, d, J=8,4 Hz), 6,27(1H, dd, J=l,8 e 2,7 Hz), 6,56 (1H, t, J=2,7 Hz), 7,19 (1H, t, J=l,8 Hz). IV (CHCI3) : 3452, 3031, 3018, 3006, 2925, 2871, 2662, 109 1736, 1710, 1634, 1609, 1556, 1498/cm.
[α] D= +43,1° (MeOH, c=l,01, 23 °C) . N° 2a-l92 CDC13 300 MHz 0, 96 (1H, d, J=10,5 Hz), 1,11 e 1,21 (cada 3H, cada s) , 1,43 (3H, t, J=7,5 Hz), 1,54-2,44 (14H, m) , 3,93 (2H, q, J=7,5
Hz), 4,21 (1H, m) , 5,33-5,51(2H, m), 5,94(1H, J=8,4 Hz), 6,27 (1H, dd, J=1, 8 e 2,7 Hz), 6,62(1H, t, J=2,7 Hz), 7,26 (1H, t, J=l,8 Hz) . IV (CHCI3) : 3630, 3452, 3032, 3018, 3006, 2925, 2871, 2661, 1735, 1710, 1633, 1610, 1555, 1497/cm.
[a]D= +40,1° (MeOH, c=l, 00, 23 °C) . N° 2a-l93 CDCI3 300 MHz 0,95(1H, d, J=10,2 Hz), 1,10 e l,22(cada 3H, cada s), 1,53-2,49(14H, m), 2,58(3H, s), 4,21(1H, m) , 5, 35-5, 54(2H, m), 6, 15 (1H, d, J=8,1 Hz), 6,52(1H, dd, J=l,8 e 3,6 Hz), 7,29 (1H, t, J=3,6 Hz), 7,94 (1H, t, J=l,8 Hz). IV (CHCI3) : 3516, 3450, 3410, 3152, 3027, 3015, 2925, 2871, 2670, 1732, 1648, 1574, 1509/cm.
[a] D= +45,0° (MeOH, c=l,01, 25 °C) . N° 2a-l94 CDCI3 300 MHz 0,99(1H, d, J=10,2 Hz), 1,11 e 1,24 (cada 3H, cada s) , 1,52-2,53(14H, m) , 4,34(1H, m) , 5,33-5,57(2H, m) , 6,21(1H, d, J=8, 6 Hz), 7,35-7,50 (2H, m) , 7,83(1H, s) 7,86(1H, m) , 8,31 (1H, m). 110 IV (CHC13) : 3443, 3067, 3013, 2925, 2870, 2665, 1708, 1651, 1515, 1493/cm.
[α] D= +55,7° (MeOH, c=l,01, 23 °C) . N° 2a-l95 CDC13 300 MHz 1,01 (1H, d, J=10,0 Hz), 1,06 e l,26(cada 3H, cada s), 1,50-2, 64(14H, m), 2,68(3H, s), 4,40(1H, m) , 5,36-5,61(2H, m), 6,02(1H, d, J=9,4 Hz), 7,30-7,42 (2H, m), 7,73-7, 86 (2H, m) . IV (CHCI3): 3510, 3434, 3062, 3029, 3014, 2924, 2871, 2669, 1708, 1650, 1563, 1539, 1500/cm.
[a] D= +72,4° (MeOH, c=l, 00, 23 °C) .
p.f. 111,0-112,0 °C N° 2a-l96 CDCI3 300 MHz 0,42 e 1,04 (cada 3H, cada s), 0,80(1H, d, J=10,0 Hz), 1,11-2,48(14H, m), 2,24(3H, s), 4,02(1H, m) , 5,23-5, 44(2H, m), 5,53(1H, d, J=8,8 Hz), 7,27-7,31 (2H, m), 7,42-7,48 (3H, m), 7, 93(1H, s) . IV (CHCI3): 3419, 3114, 3025, 3006, 2924, 2871, 2662, 1737, 1709, 1636, 1540, 1519/cm.
[a] D= +43,7° (MeOH, c=l,01, 23 °C) . N° 2a-l97 CDCI3 300 MHz 0,95(1H, d, J=10,0 Hz), 1,09 e 1,23 (cada 3H, cada s) , 1,54-2,46(18H, m), 2,77(4H, s 1), 4,21(1H, m) , 5,32-5,54 (2H, m) , 6, 02 (1H, d, J=8,6 Hz), 7,43(1H, s) . IV (CHCI3) : 3445, 3101, 3024, 3014, 2928, 2865, 2661, 111 1739, 1708 1646, 1550, 1507/cm.
[α] D= +51,9° (MeOH, c=l,01, 23 °C) . N° 2a-l98 CDCI3 300 MHz 0, 96 (1H, d, J=10,2 Hz), 1,11 e l,22(cada 3H, cada s) , 1,50-2,44 (14H, m) , 4,24(1H, m) , 4,42(2H, s) , 5, 35-5, 49 (2H, m) , 6,25 (1H, d, J=8,1 Hz), 7,33(1H, m) , 7,43(1H, dd, J=l,5 e 7,5
Hz) , 7,49(1H, d, J=8, 1 Hz), 7, 60-7, 63 (1H, m) , 7,68(1H, dd, 1—1 II 8 e 7,8 Hz), 8,02(1H, d, J=1,8 Hz), 8,19(1H, dd, J=1,5 e ι—1 00 Hz) . IV (CHCI3) : 3448, 3030, 3012, 2925, 2870, 1739, 1708, 1671 , 1588, 1559, 1514, 1472/cm. [a] D= +56,9° (MeOH, c=l,01, 24 °C) . N° 2a-l99 CDCI3 300 MHz 0, 96 (1H, d, J=10,2 Hz), 1,11 e 1,22 (cada 3H, cada s) , 1.51- 2,46 (14H, m) , 3,40(1H, m) , 3,76(1H, m) , 4,24(1H, m) , 5,33-5,51 (3H, m) , 6,25(1H, m) , 7,16(1H, m) , 7,24-7,33 (2H, m) , 7,4 6(1H, d, J=7,5 Hz), 7,52-7, 60(2H, m) , 7,85(1H, dd, J=l,8 e 5 Hz). IV (CHCI3): 3583, 3447, 3062, 3028, 3013, 2924, 2871, 2663, 1708, 1651, 1600, 1557, 1514, 1471/cm.
[a] D= +54,8° (MeOH, c=l, 00, 23 °C) . N° 2a-200 CDCI3 300 MHz 0,96(1H, d, J=10,2 Hz), 1,12 e 1,23 (cada 3H, cada s) , 1.51- 2,46(14H, m), 4,25(1H, m), 5,34-5,51(2H, m), 6,25(1H, d, 112 J=8,4 Hz), 7,02 e 7,10(cada 1H, cada d, J=12,3 Hz), 7,23-7,33 (4H, m) , 7,50(1H, m) , 7,64(1H, dd, J=l,8 e 7,8 Hz), 7,82 (1H, d, J=l,8 Hz) . IV (CHC13) : 3450, 3060, 3025, 3014, 2925, 2871, 2662, 1708, 1653, 1596, 1542, 1513, 1473/cm.
[a] D= +62,5° (MeOH, c=l, 00, 24 °C) . N° 2a-201 CDCI3 300 MHz 0,95(1H, d, J=9, 9 Hz), 1,15 e 1,22 (cada 3H, cada s) , 1,55-2, 60(14H, m) , 4,26(1H, m) , 5, 35-5, 63(2H, m) , 7,14(1H, d, J=9, 9 Hz), 7,34 e 7,40 (cada 1H, cada d, J=12,9 Hz), 7,62-7,73(4H, m), 8,25-8,30(2H, m), 8,72(1H, d, J=l,5 Hz). IV (CHCIs) : 3443, 3389, 3297, 3061, 3030, 3016, 2925 2870, 1708 1652, 1603, 1521, 1483, 1472, 13 0 9/cm. [a]D— +61, 1 0 (MeOH, c=l, PO CM 1—1 0 °C) . N° 2a-202 CDCI3 300 MHz 0, 96 (1H, d, J=10,2 Hz), 1,09 e l,22(cada 3H, cada s) , 1,52-2,43(14H, m), 2,63(3H, s), 4,25(1H, m) , 5,33-5,49(2H, m), 6,19(1H, d, J=8,4 Hz), 7,10 e 7,58(cada 2H, cada d, J=9,0 Hz), 7,21 (1H, m), 7,30-7,32 (2H, m), 7,46(1H, d, J=7,5 Hz) IV (CHCI3) : 3511, 3453, 3062, 3032, 3014, 2925 2870, 1739, 1708, 1650, 1595, 1556, 1516, 1482, 1471/cm.
[a] D= +60,2° (MeOH, c=l,01, 25 °C) . N° 2a-203 CDCI3 300 MHz 0,96(1H, d, J=10,5 Hz), 1,09 e 1,23(cada 3H, cada s), 113 1,52-2,43(14Η, m) , 4,23(1H, m) , 5,35-5,51(2H, m) , 5,93(1H, d J=8,7 Hz), 6,5 6 (1H, dd, J=0,9 e 1,8Hz), 7,43(1H, t, J=l,8 Hz) 7,92 (1H, dd, J=0,9 e 1,8 Hz). 2667 IV (CHC13) : 3517, 1708, 1656, 1588, [a]D= +46,7° (MeOH, N° 2b-l [a]D= +25,6° (MeOH, N° 2b-2 [a] D= +38,9o (MeOH, N° 2c-l [a]D= +60,5° (MeOH, N° 2c-2 [a] D= +55, 8 0 (MeOH, N° 2c-3 [a]D= +54,7° (MeOH, N° 2d-l [a] D= -6,2° (MeOH, N° 2d-2 3450, 3134, 3031, 1570, 1514/cm. c=0,92, 25 °C). c=l,01, 23 °C). c=l,01, 24 °C). c=l,01, 22 °C). c=0,92, 22 °C). c=l,01, 22 °C). c=l,00, 21 °C). 3008, 2925, 2870, 114 [ α] D= +15,8° (MeOH, c=0,34, 22° C) N° 2d-3 [a] D= +31,6° (MeOH, c=l,01, 22 °C) \—1 1 ω C\1 o 3 O 1 II Ω (MeOH, c=l,00, 22 °C). N° 2e-2 O 00 \—1 1 II Ω (MeOH, c=l,02, 23 °C). N° 2e-3 [a] D= -6,7° (MeOH, c=l,01, 23 °C). N° 2f-l O OO oo + II Ω (MeOH, c=l,01, 23 °C). N° 2f-2 O OO C\] 1 II Ω (MeOH, c=l,00, 22 °C). N° 2f-3 [a] D= -3,5° (MeOH, c=l,01, 22 °C) . N° 2g-l 115 [α] D= +54,6° (MeOH, c=l,01, 24 °C) .
Os compostos preparados nos Exemplos acima foram avaliados para actividade in vivo e in vitro segundo o método descrito nos exemplos Experimentais abaixo.
Experiência 1 Ligação ao Receptor da PGD2
Materiais e Método (1) Preparação da Fracção da Membrana de Plaquetas Humanas
Obteve-se uma amostra de sangue utilizando uma seringa de plástico contendo citrato de sódio a 3,8% a partir de veias de voluntários saudáveis (machos e fêmeas adultos), colocou-se num tubo de ensaio em plástico e misturou-se suavemente por inversão. Centrifugou-se em seguida a 1800 rpm, 10 min à temperatura ambiente e recolheu-se o sobrenadante contendo PRP (plasma rico em plaquetas). Recentrifugou-se o PRP a 2300 rpm, 22 min à temperatura ambiente para se obter plaquetas. Homogeneizou-se as plaquetas com um homogeneizador (Ultra-Turrax) após o que se centrifugou 3 vezes a 20.000 rpm, 10 min a 4 °C para se obter a fracção das membranas de plaquetas. Após a determinação da proteína, a fracção das membranas foi ajustada até 2 mg/mL e mantidas num frigorífico a -80 °C até serem utilizadas. (2) Ligação ao Receptor da PGD2 A uma solução da reacção de ligação (Tris 50 mM/HCl, pH 7,4, MgCl2 5 mM) (0,2 ml) adicionou-se a fracção das membranas de plaquetas (0,1 mg) e [3H]PGD2 5 nM (115 Ci/mmol), e fez-se 116 reagir a 4 °C durante 90 min. Uma vez concluída a reacção, filtrou-se a mistura reaccional através de um papel de filtro em fibra de vidro, lavou-se várias vezes com soro fisiológico arrefecido e mediu-se a radioactividade retida no papel de filtro. A ligação específica foi calculada subtraindo a ligação não específica (a ligação na presença de PGD2 10 μΜ) da ligação total. A actividade inibidora da ligação de cada composto foi exprimida como a concentração necessária para 50% de inibição (IC50) , a gual foi determinada representando uma curva de substituição através da representação da proporção de ligação (%) na presença de cada composto, em gue a proporção de ligação na ausência de um composto de ensaio é -100%. Os resultados são mostrados no Quadro abaixo. Número do composto Actividade (μΜ) 2a-4 0,54 2a-17 0, 12 2a-21 5,2 2a-2 8 0,046 2a-95 1, 6 2a-l0 9 0,003
Experiência 2 Avaliaçao da Actividade Antagonista do Receptor da PGD2 Utilizando Plaguetas Humanas
Obteve-se sangue periférico de um voluntário saudável utilizando uma seringa à gual se adicionou previamente 1/9 do volume de solução de ácido cítrico/dextrose. Submeteu-se a seringa a centrifugação a 180 g durante 10 min para se obter o sobrenadante (PRP: plasma rico em plaquetas). Lavou-se 3 vezes o RRP resultante com um tampão de lavagem e contou-se o número de plaquetas com um microcontador de células. Aqueceu-se uma 117 suspensão ajustada para conter plaquetas a uma concentração final de 5 x 108/mL a 37 °C, e submeteu-se em seguida a pré-tratamento com 3-isobutil-l-metilxantina (0,5 mM) durante 5 min. À suspensão adicionou-se um composto de ensaio a várias concentrações. Dez minutos depois, induziu-se a reacção através da adição de PGD2 0,1-2,0 μΜ, e parou-se 15 minutos mais tarde através da adição de HC1. Destruiu-se as plaquetas com um homogeneizador de ultra-sons. Após centrifugação, determinou-se o cAMP no sobrenadante através de um radioensaio. O antagonismo do receptor de PGD2 pelo fármaco foi avaliado como se segue. Determinou-se a cada concentração a proporção de inibição relativamente ao aumento de cAMP pela adição de PGD2 e calculou-se em seguida a concentração de fármaco necessária para 50% de inibição (IC50) . Os resultados são mostrados no Quadro abaixo. Número do composto Inibição do Aumento do cAMP de Plaquetas
Humanas (IC50) (μΜ) 2a-2 0,77 2a-4 0,49 2a-35 1,52 2a-7 5 0,71
Experiência 3 Experiência Utilizando o Modelo da Obstrução
Nasal O método utilizado para medir a resistência da cavidade nasal e avaliar a antiobstrução nasal utilizando um porquinho--da-índia é descrito a seguir.
Tratou-se uma solução de ovalbumina a 1% (OVA) com um nebulizador ultrassónico para se obter um aerossol. Sensibilizou-se um porquinho-da-índia Hartley macho inalando 2 118 vezes o aerossol durante 10 min em intervalos de uma semana. Sete dias após a sensibilização, expôs-se o porquinho-da-índia a um antigénio para iniciar a reacção. Em seguida fez-se uma incisão na traqueia sob anestesia com pentobarbital (30 mg/kg, i.p.) e inseriu-se cânulas na traqueia dos lados pulmonar e da cavidade nasal. O canal inserido do lado pulmonar foi ligado a um ventilador que proporciona 4 mL de ar 60 vezes/min. Depois de parar a respiração espontânea de um porquinho-da-índia com Garamina (2 mg/kg, i.v.), forneceu-se ar do lado do focinho com um ventilador à frequência de 70 vezes/min e mediu-se o caudal de 4 mL de ar/vez, e a pressão atmosférica necessária para arejamento utilizando um transdutor adaptado à bifurcação. A medição foi utilizada como um parâmetro da resistência da cavidade nasal. A exposição de um antigénio foi realizada produzindo um aerossol de solução de OVA a 3% OVA durante 3 min entre o ventilador e a cânula da cavidade nasal. Injectou-se o fármaco de ensaio por via intravenosa 10 min antes da exposição ao antigénio. Mediu-se continuamente a resistência nasal entre os 0 e os 30 min e exprimiu-se o efeito como a taxa de inibição relativamente à obtida para o veículo utilizando a AUC durante 30 min (no eixo vertical, resistência da cavidade nasal (cm H20), e no eixo horizontal, tempo (0-30 min)) como uma indicação. O resultado é mostrado abaixo. 119 Número do Composto Taxa de inibição (%) Notas 1 mg/kg (i.v.) 2a-4 60 2a-21 52 2a-2 8 54 2a-95 77 2a-96 77 10 mg/kg (p.o.) 2a-l0 9 73 2a-l10 66 10 mg/kg (p.o.) 2a-l94 79 Formulação 1 Preparação de Comprimidos Comprimidos contendo, cada um, 40 mg de principio activo foram preparados de um modo convencional.
Lisboa, 12 de Outubro de 2006 120

Claims (10)

  1. REIVINDICAÇÕES 1. Composto da fórmula (Ib):
    (Ib) em que e em que A interrompido grupo oxo, e/
    e alquileno o qual esta opc por um heteroátomo ou fenileno, ou tem uma ligação insaturada; ionalmente contém um B é hidrogénio, alquilo, aralquilo ou acilo; R é COORi, CH2OR2 ou CON(R3)R4; Ri é hidrogénio ou alquilo; R2 é hidrogénio ou alquilo; R3 e R4 são, cada um, independentemente hidrogénio, alquilo, hidroxilo ou alquilsulfonilo; 1 naftileno Xi é uma ligação simples, fenileno, tiofenodiilo, indolediilo ou oxazolediilo; X2 é uma ligação simples, -N=N-, -N=CH-, -CH=N-, -CH=N-N-, -CH=N-0-, -C=NNHCSNH-, -C=NNHCONH-, -CH=CH-, -CH(OH)-, -C (Cl) =C (Cl)-, -(CH2)n-, etinileno, -N(R5)-, -N(R5i)CO-, -N (R52) S02-, -N(R53)CON(R54)-, -con(r55)- -so2n(r56)-, -0-, -s-, -S0-, -S02-, -C0-, oxadiazolediilo, tiadiazolediilo ou tetrazolediilo; X3 é alquilo, alcenilo, alcinilo, arilo, aralquilo, grupo heterociclico, cicloalquilo, cicloalcenilo, tiazolinilidenometilo, tiazolidinilidenometilo, -CH=NR6 ou -N=C(R7)R8; R5, R51, R52, R53, R54, R55 e R56 São, cada um, hidrogénio ou alquilo; R6 é hidrogénio, alquilo, hidroxilo, alcoxilo, carba-moiloxilo, tiocarbamoiloxilo, ureido ou tioureido; R7 e R8 são, cada um, independentemente alquilo, alcoxilo ou arilo; e n é 1 ou 2; em que um substituinte cíclico pode ter um até três substituintes seleccionados do grupo constituído por nitro, alcoxilo, sulfamoílo, amino substituído ou não substituído, acilo, aciloxilo, hidroxilo, halogéneo, alquilo, alcinilo, carboxilo, alcoxicarbonilo, aralcoxi-carbonilo, ariloxi-carbonilo, mesiloxilo, ciano, alceni-loxilo, hidroxialquilo, trifluorometilo, alquiltio, -N=PPh3, oxo, tioxo, hidroxi-imino, alcoxiimino, fenilo e alquilenodioxilo, ou o seu sal ou hidrato deste; com a condição de que estejam excluídos os compostos (a) em que Xi e X2 são uma ligação simples, e X3 é fenilo; (b) em que Xi é uma ligação simples, X2 é -0- e X3 é benzilo; 2 e
    "NHC0~0~C(CH3)3 <j*| (f) ^^^002CH2 NHC0~0-C(CH3)3
  2. 2. Composto da reivindicação 1, um seu sal ou hidrato, em que:
  3. 3. Composto da reivindicação 2, um seu sal ou hidrato, em que R é COORi.
  4. 4. Composto da reivindicação 2, um seu sal ou hidrato, em que Xi é fenileno ou tiofenodiilo, X2 é uma ligação simples, -N=N-, -CH=CH-, etinileno, -0-, -S-, -C0-, -CON (R55) -, -N (R51) C0- e X3 é fenilo ou tienilo. 3
  5. 5. Composto da reivindicação 1, um seu sal ou hidrato que: em
    e
  6. 6. Composto da reivindicação 5, um seu sal ou hidrato, em que B é hidrogénio, Xi e X2 são ambos uma ligação simples, X3 é tienilo, tiazolilo, tiadiazolilo, isotiazolilo, pirrolilo, piridilo, benzofurilo, benzimidazolilo, benzotienilo, dibenzofurilo, dibenzotienilo, quinolilo ou indolilo.
  7. 7. Composto da reivindicação 5, um seu sal ou hidrato, em que Xi é fenileno tiofenodiilo, indolediilo ou oxazolediilo, X2 é uma ligação simples, -N=N-, -CH=CH-, etinileno, -S- ou -0-, e X3 é arilo ou um grupo heterociclico.
  8. 8. Composto da fórmula (Ib) abaixo, para utilização num método para tratar doenças em que está envolvida a disfunção de mastócitos, contracção da traqueia, asma, rinite alérgica, conjuntivite alérgica, urticária, lesão devido a reperfusão isquémica, obstrução nasal e inflamação: 4 A—R Ob) N—CQ-Xi-Xt—Xs i B em que e
    em que A é alquileno o qual está opcionalmente interrompido por um heteroátomo ou fenileno, contém um grupo oxo, e/ou tem uma ligação insaturada; B é hidrogénio, alquilo, aralquilo ou acilo; R é COORi, CH2OR2 ou CON(R3)R4; Ri é hidrogénio ou alquilo; R2 é hidrogénio ou alquilo; R3 e R4 são, cada um, independentemente hidrogénio, alquilo, hidroxilo ou alquilsulfonilo; Xi é uma ligação simples, fenileno, naftileno, tiofenodiilo, indolediilo ou oxazolediilo; X2 é uma ligação simples, -N=N-, -N=CH-, -CH=N-, -CH=N-N-, -CH=N-0-, -C=NNHCSNH-, -C=NNHCONH-, -CH=CH-, -CH(OH)-, -C (Cl) =C (Cl)-, -(CH2)n-, etinileno, -N(RS)-, -N(RSi)CO-, -N(R52)S02-, -N (R53) CON (R54) -, -CON(R55)- -S02N(R56)-, -0-, -S-, 5 -CO-, oxadiazolediilo, tiadiazolediilo -SO-, -so2-, ou tetrazolediilo; X3 é alquilo, alcenilo, alcinilo, arilo, aralquilo, grupo heterocíclico, cicloalquilo, cicloalcenilo, tiazolinilidenometilo, tiazolidinilidenometilo, -CH=NR6 ou -N=C(R7)R8; R5, R5i, R52, R53, R54, R55 e R5 6 são, cada um, hidrogénio ou alquilo; R6 é hidrogénio, alquilo, hidroxilo, alcoxilo, carbamoiloxilo, tiocarbamoiloxilo, ureido ou tioureido; R7 e R8 são, cada um, independentemente alquilo, alcoxilo ou arilo; e n é 1 ou 2; em que um substituinte cíclico pode ter um até três substituintes seleccionados do grupo constituído por nitro, alcoxilo, sulfamoilo, amino substituído ou não substituído, acilo, aciloxilo, hidroxilo, halogéneo, alquilo, alcinilo, carboxilo, alcoxicarbonilo, aral-coxicarbonilo, ariloxicarbonilo, mesiloxilo, ciano, alceniloxilo, hidroxialquilo, trifluorometilo, alquiltio, -N=PPh3, oxo, tioxo, hidroxiimino, alcoxiimino, fenilo e alquilenodioxilo, ou o seu sal ou hidrato deste; com a condição de que estejam excluídos os compostos (a) em que Xi e X2 são uma ligação simples e X3 é fenilo; (b) em que Xi é uma ligação simples, X2 é -0- e X3 é benzilo.
  9. 9. Utilização de um antagonista da PGD2 compreendendo um composto da fórmula (Ib) como definido na reivindicação 8, ou um seu sal ou hidrato, como um princípio activo no fabrico de uma composição farmacêutica para o tratamento de doenças nas quais está envolvida a disfunção de mastócitos, contracção da traqueia, asma, rinite alérgica, conjuntivite alérgica, urticária, lesão devido a reperfusão isquémica, obstrução nasal e inflamação. 6
  10. 10. Utilização de um antagonista da PGD2 compreendendo um composto da fórmula (Ib) como definido na reivindicação 9, ou um seu sal ou hidrato, como um principio activo no fabrico de uma composição farmacêutica para o tratamento de doenças nas quais está envolvida a disfunção de mastócitos, contracção da traqueia, asma, rinite alérgica, conjuntivite alérgica, urticária, lesão devido a reperfusão isquémica, obstrução nasal e inflamação. Lisboa, 12 de Outubro de 2006 7
PT96918841T 1995-06-21 1996-06-19 Derivados amino bicíclicos e antagonistas de pgd 2 contendo esses derivados PT837052E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP15457595 1995-06-21

Publications (1)

Publication Number Publication Date
PT837052E true PT837052E (pt) 2006-12-29

Family

ID=15587229

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96918841T PT837052E (pt) 1995-06-21 1996-06-19 Derivados amino bicíclicos e antagonistas de pgd 2 contendo esses derivados

Country Status (25)

Country Link
US (3) US6172113B1 (pt)
EP (1) EP0837052B1 (pt)
JP (1) JP3195361B2 (pt)
KR (1) KR100428601B1 (pt)
CN (1) CN1134411C (pt)
AT (1) ATE337294T1 (pt)
AU (1) AU714312B2 (pt)
BR (1) BR9608498B1 (pt)
CA (1) CA2225250C (pt)
CZ (1) CZ285870B6 (pt)
DE (1) DE69636478T2 (pt)
DK (1) DK0837052T3 (pt)
EA (1) EA000987B1 (pt)
ES (1) ES2270438T3 (pt)
HU (1) HUP9802678A3 (pt)
IL (1) IL122332A0 (pt)
IS (1) IS2359B (pt)
MX (1) MX9710256A (pt)
NO (1) NO975994L (pt)
NZ (1) NZ310559A (pt)
PL (1) PL185107B1 (pt)
PT (1) PT837052E (pt)
TR (1) TR199701667T2 (pt)
TW (1) TW513422B (pt)
WO (1) WO1997000853A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE295360T1 (de) * 1996-12-12 2005-05-15 Shionogi & Co Kondensierte heterocyclische benzolcarbonsäureamid-derivate und diese enthaltende pgd2 antagonisten
ES2181039T3 (es) * 1996-12-13 2003-02-16 Shionogi & Co Derivados de benzotiofenocarboxamida y antagonistas de pgd2 que los comprenden.
EP0980868A4 (en) * 1997-04-28 2001-01-24 Nitto Denko Corp OPTICALLY ACTIVE MONOMER, LIQUID CRYSTALLINE POLYMER AND OPTICAL ELEMENT
US6225336B1 (en) 1997-09-19 2001-05-01 Shionogi & Co., Ltd. Compounds having [2.2.1] bicyclo skeleton
ATE298747T1 (de) * 1998-03-31 2005-07-15 Shionogi & Co Verfahren zur herstellung von 5- hydroxybenzo(b)thiophen-3-carbonsäure
US6506789B2 (en) 1998-06-03 2003-01-14 Shionogi & Co., Ltd. Methods for the treatment of itching comprising administering PGD2 receptor antagonist
CN1198649C (zh) * 1998-06-03 2005-04-27 盐野义制药株式会社 用于治疗瘙痒的含pgd2受体拮抗剂的药物组合物
WO2000030683A1 (fr) * 1998-11-19 2000-06-02 Shionogi & C0., Ltd. Composes prophylactiques et/ou therapeutiques destines a des maladies du systeme nerveux central et possedant des composes antagonistes du recepteur de txa2 et/ou inhibiteurs de la txa2 synthase
JP3828364B2 (ja) * 1999-03-10 2006-10-04 塩野義製薬株式会社 ［２．２．１］および［３．１．１］ビシクロ骨格を有するｐｇｄ２／ｔｘａ２両受容体拮抗性医薬組成物
CA2380206A1 (en) * 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Pharmaceutical compositions exhibiting thrombopoietin receptor agonism
EP1201238A4 (en) * 1999-07-29 2003-01-15 Ono Pharmaceutical Co SULPHONAMIDE DERIVATIVES AND HEALING AGENTS FOR ALLODYNIA
NZ540351A (en) 1999-11-26 2006-05-26 Shionogi & Co NPY Y5 antagonists
NZ521192A (en) 2000-03-09 2005-01-28 Ono Pharmaceutical Co Indole derivatives, process for preparation of the same and use thereof
JP2003528076A (ja) * 2000-03-20 2003-09-24 メルク シャープ エンド ドーム リミテッド スルホンアミド置換架橋ビシクロアルキル誘導体
EP1274457B1 (en) * 2000-04-12 2005-11-30 Merck Frosst Canada & Co. Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
EP1295872A4 (en) * 2000-06-02 2007-05-16 Shionogi & Co ANTAGONIST MEDICINAL PRODUCT FOR PGD2 / TXA2 RECEPTORS
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
US6835752B2 (en) * 2000-08-22 2004-12-28 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient
CA2419722A1 (en) * 2000-09-01 2003-02-21 Masaki Asada Benzoic acid derivatives and drugs containing the same as the active ingredient
US7273883B2 (en) 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
AU2002213505A1 (en) * 2000-10-17 2002-04-29 Shionogi & Co., Ltd Process for the preparation of pgd2 antagonist
JPWO2002036583A1 (ja) * 2000-11-01 2004-03-11 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗性医薬組成物
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
WO2003039475A2 (en) * 2001-11-07 2003-05-15 Millennium Pharmaceuticals, Inc. Methods of identifying and using modulators of fractalkine receptor
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
ATE479686T1 (de) 2002-10-30 2010-09-15 Merck Frosst Canada Ltd Pyridopyrrolizin- und pyridoindolizinderivate
DK1731512T3 (en) 2004-03-05 2015-01-05 Nissan Chemical Ind Ltd Isoxazoline-substituted benzamide AND INSTRUMENTS FOR COMBATING HARMFUL ORGANISMS
BRPI0508540B8 (pt) 2004-03-11 2021-05-25 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
JPWO2006068162A1 (ja) * 2004-12-24 2008-06-12 塩野義製薬株式会社 慢性閉塞性肺疾患の治療剤
CA2601979C (en) * 2005-04-21 2014-06-17 Laboratoires Serono S.A. 2,3 substituted pyrazine sulfonamides
EP2155675B1 (en) * 2007-06-12 2014-02-19 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
CN102341385B (zh) * 2009-03-09 2014-01-15 大鹏药品工业株式会社 能够抑制前列腺素d合酶的哌嗪化合物
EP2516416A1 (en) 2009-12-23 2012-10-31 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
AR088020A1 (es) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CA2817319A1 (en) 2010-11-09 2012-05-18 Ironwood Pharmaceuticals, Inc. Triazole derivatives as sgc stimulators
US9156830B2 (en) 2011-05-17 2015-10-13 Shionogi & Co., Ltd. Heterocyclic compounds
CN104066731B (zh) 2011-12-27 2016-06-15 铁木医药有限公司 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
KR102362835B1 (ko) 2013-03-15 2022-02-14 사이클리온 테라퓨틱스, 인크. ｓＧＣ 자극인자
CA2933250A1 (en) 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
JP2017527604A (ja) 2014-09-17 2017-09-21 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激剤
MX2017003516A (es) 2014-09-17 2017-07-28 Ironwood Pharmaceuticals Inc Derivados de pirazol como estimuladores de guanilato ciclasa soluble (sgc).
US20180021302A1 (en) 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US10889577B2 (en) 2016-07-07 2021-01-12 Cyclerion Therapeutics, Inc. Solid forms of an sGC stimulator
MX2019000103A (es) 2016-07-07 2019-04-22 Ironwood Pharmaceuticals Inc Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc).

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628061A (en) 1981-12-23 1986-12-09 National Research Development Corporation Prostaglandins
US4837234A (en) 1981-12-23 1989-06-06 National Research Development Corporation Prostaglandins
US4526901A (en) * 1984-01-26 1985-07-02 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane substituted oxamide prostaglandin analogs and their use in treating thrombolytic disease
JPS6149A (ja) 1984-06-12 1986-01-06 Ono Pharmaceut Co Ltd 新規な１３―アザ―１４―オキソ―ＴｘＡ２類似化合物およびそれらを有効成分として含有するトロンボキサン起因疾患治療剤
CA1278577C (en) * 1985-11-18 1991-01-02 Tatsuo Tsuri Bicyclic sulfonamide derivatives
CA1294974C (en) 1987-05-08 1992-01-28 Sanji Hagishita Bicyclic sulfonamide derivatives and process therefor
EP0312906A3 (en) * 1987-10-23 1990-09-05 Ono Pharmaceutical Co., Ltd. Novel sulfonamide derivatives
JP2565746B2 (ja) * 1987-10-23 1996-12-18 小野薬品工業株式会社 新規な炭素環系スルホンアミド誘導体
JPH0262546A (ja) 1988-08-30 1990-03-02 Asahi Chem Ind Co Ltd 改良された光学用感光性樹脂組成物
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides

Also Published As

Publication number Publication date
KR19990028261A (ko) 1999-04-15
DE69636478D1 (de) 2006-10-05
US6498190B1 (en) 2002-12-24
CN1193315A (zh) 1998-09-16
BR9608498A (pt) 1999-07-06
CN1134411C (zh) 2004-01-14
US6384075B1 (en) 2002-05-07
WO1997000853A1 (fr) 1997-01-09
HUP9802678A3 (en) 1999-12-28
CZ285870B6 (cs) 1999-11-17
EA199800074A1 (ru) 1998-08-27
US6172113B1 (en) 2001-01-09
DK0837052T3 (da) 2007-01-02
NZ310559A (en) 1999-05-28
KR100428601B1 (ko) 2004-09-16
AU714312B2 (en) 1999-12-23
EA000987B1 (ru) 2000-08-28
DE69636478T2 (de) 2007-04-19
IS2359B (is) 2008-04-15
IS4623A (is) 1997-11-28
HUP9802678A2 (hu) 1999-02-01
EP0837052A1 (en) 1998-04-22
CA2225250C (en) 2005-03-22
NO975994D0 (no) 1997-12-19
TW513422B (en) 2002-12-11
TR199701667T2 (xx) 1999-10-21
CZ401397A3 (cs) 1998-04-15
JP3195361B2 (ja) 2001-08-06
AU6137096A (en) 1997-01-22
IL122332A0 (en) 1998-04-05
PL324115A1 (en) 1998-05-11
MX9710256A (es) 1998-03-31
EP0837052B1 (en) 2006-08-23
ES2270438T3 (es) 2007-04-01
ATE337294T1 (de) 2006-09-15
EP0837052A4 (en) 2001-12-19
PL185107B1 (pl) 2003-02-28
CA2225250A1 (en) 1997-01-09
BR9608498B1 (pt) 2008-11-18
NO975994L (no) 1998-02-23

Similar Documents

Publication Publication Date Title
PT837052E (pt) Derivados amino bicíclicos e antagonistas de pgd 2 contendo esses derivados
JP5206405B2 (ja) イミダゾ［１，２−ａ］ピリジン誘導体：製造および医薬用途
ES2929283T3 (es) Moduladores del receptor de relaxina 1
JPWO2009005076A1 (ja) アミド化合物
JP4748338B2 (ja) ベンゼン誘導体及びその医薬用途
KR20090007571A (ko) Ｎｐｙ ｙ5 수용체 길항 작용을 갖는 아민 유도체
JPWO2008123207A1 (ja) オルニチン誘導体
IL130660A (en) History of benzothiophenecarboxamide and PGD2 antibodies containing them
JP6314129B2 (ja) グアニジノ安息香酸エステル化合物
JPWO2008133155A1 (ja) 二環式ヘテロ環化合物
WO2009067856A1 (en) Histone deacetylase inhibitor, composition and use thereof
CN115960148B (zh) 一种新型的胞苷衍生物及其药物组合物和用途
ES2973850T3 (es) Derivados del benzoimidazol como agentes anticancerígenos
EP1016660B1 (en) Compounds having 2.2.1]bicyclo skeleton
JP2011088826A (ja) 芳香族カルボン酸化合物
TWI247007B (en) Method for preparing 5-hydroxybenzo [b] thiophene-3-carboxylic acid derivatives
ES2348360T3 (es) Derivados de bencimidazol: preparación y aplicaciones farmacéuticas.
JP3701878B2 (ja) ビシクロ環系アミノ誘導体およびそれを含有するｐｇｄ２拮抗剤
PT96066B (pt) Proceso de preparacao de derivados heterociclicos de acilaminotiazoles
JPS63159359A (ja) 安息香酸誘導体
MXPA99005469A (en) Benzothiophenecarboxamide derivatives and pgd2